GOVERNING BOARD
Carlos Fernandez-del Castillo, MD, President  
Anirban Maitra, MBBS, Past President  
Miklos Sahin-Toth, PhD, President-Elect  
Ashok Saluja, PhD, Secretary-Treasurer  
Darwin Conwell, MD – Councilor  
Margaret Tempero, MD - Councilor  
Anil Rustgi, MD - Councilor

COURSE DIRECTOR
Ashok K. Saluja, PhD, Course Director  
Carlos Fernandez-del Castillo, MD, Course Co-Director

APA CONTACT INFORMATION
Ashok K. Saluja, PhD  
APA Secretary-Treasurer  
Professor & Vice Chair, Surgery  
University of Miami Miller School of Medicine  
asaluja@miami.edu

PO Box 352406  
Miami, FL 33135

Telephone | 305-243-6039  
Fax | 305-243-6263  
Email | apa@miami.edu

www.american-pancreatic-association.org
MESSAGE FROM THE PRESIDENT

Welcome to Boston!

On behalf of the board of the American Pancreatic Association, thank you for attending our 47th Annual Meeting. We received over 300 abstracts, and as you can see from the program, the oral presentations and posters showcase cutting edge basic, translational, and clinical science, including topics that just 10 years ago would have seemed like science fiction. We also have several mini symposia on novel or controversial clinical and basic science topics, “meet the professor” breakfast sessions, and our traditional state of the art lectures, where you will hear about the stressed acinar cell and what the future looks like for treating pancreatic cancer.

Our pre-meeting conference is on Intraductal Papillary Mucinous Neoplasms, and our intent was to bring basic scientists and clinicians together to discuss what needs to be done to advance the field in this disease. Experts from many parts of the world have come to participate, and we hope you will take advantage of their presence.

We continue to benefit from the incredible support of several foundations that enhance our program. This year, for the first time, the Hirshberg symposium will focus on Pancreatic Cancer Surgery, and the Kenner foundation has brought distinguished representatives to speak about biomarkers for early detection. In addition, PanCan has brought four of their young investigators to present their work. Last year we had this forum for the first time to great acclaim, and we hope it will continue in the future.

The APA meeting is unique not just for its scientific content, but also because it brings us together in the meals and social events, all of which are included with your registration. This package deal is indeed a great value, and we hope you will take advantage of it. The organizing team, in particular our secretary/treasurer Ashok Saluja and his assistant Maria Fernandez have worked very hard to make this happen, and we thank them enthusiastically.

Carlos Fernández-del Castillo, MD
Jorge and Darlene Pérez Endowed Chair in Surgery
Director, Pancreas and Biliary Surgery Program
Massachusetts General Hospital
Professor of Surgery, Harvard Medical School
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint partnership of the University of Miami Leonard M. Miller School of Medicine and American Pancreatic Association. The University of Miami Leonard M. Miller School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 28.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
This activity is designed for physicians and researchers. Upon completion of this course, participants will be able to:

1. To evaluate the potential for liquid biopsies in longitudinal monitoring of pancreatic cancer patients for evolution in the tumor genome and appearance of new therapeutic vulnerabilities.
2. To recognize the use of liquid biopsies as a potential earlier marker of disease relapse or recurrence.
3. To explain the implications of an incidentally-discovered solid lesion in the pancreas.
4. To describe the diagnostic tools available in the differential diagnosis of pancreatic solid lesions.
5. To contrast the management approaches for small, incidentally discovered PNETs.
7. Differentiate chronic pancreatitis from alternative diagnoses.
8. Construct an appropriate cohort of patients at high risk of pancreatic cancer.
10. Select patients for various treatment options.

DOCUMENTATION OF ATTENDANCE FOR CME
Sign in at Registration desk, complete electronic evaluation and credit adjustment form.

EVALUATIONS & CREDIT ADJUSTMENT FORM
Conference evaluations are a valuable tool in assisting to better serve you. An e-mail with a link to the electronic evaluation form and credit adjustment form will be sent to you at the end of the program. Please complete your evaluation form on-line. We welcome your comments and suggestions. Certificates of Attendance will be e-mailed to attendees approximately 6 to 8 weeks after the conference. An outcome evaluation will be conducted 2 to 3 months following the course to measure the impact this activity has had in changing performance and patient outcomes. We encourage and appreciate your participation.

FACULTY DISCLOSURE PAGE
Disclosure and Conflict of Interest Resolution Statement
In accordance with the 2004 Updated ACCME Standards for Commercial Support the University of Miami Leonard M. Miller School of Medicine requires everyone in a position to control the content of a Continuing Medical Education activity – the Course Director(s), Planning Committee Members and all individuals participating as speakers, moderators or authors to disclose all relevant financial relationships with any commercial interest. All potential conflicts of interest are identified and resolved prior to the education activity being provided to learners. Disclosure of relevant financial relationship(s) will be provided to learners prior to the beginning of the educational activity.
SUPPORTERS
The American Pancreatic Association would like to extend a special thank you to the following organizations for their support of this meeting through educational grants:

Platinum Supporters
AbbVie
Celgene
ChiRhoClin

Gold Supporters
Hirshberg Foundation for Pancreatic Cancer Research
Kenner Family Research Fund
Massachusetts General Hospital

Silver Supporters
Allergan Foundation
Boston Scientific
Cook Medical
Digestive Care
National Pancreas Foundation
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Vay Liang W. Go, Pancreas Journal

YOUNG INVESTIGATOR AWARDS WINNERS
Toshiya Abe
Maisam Abu-El-Haija
Andreas Andreou
Jane Armstrong
Jodie Barkin
Myrriah Chavez-Tomar
Michelle Cooley
Melissa Fenech
Ming Gao
Bharti Garg
Robert Hollemans
Yinshi Huang
Wei Huang
Eliana Jones
Shingo Kagawa
Jae Seung Kang
Muhammad Kizilgul
Audrey Lane
Xuqi Li
Minyang Liu
Thomas Mace
Scott Messenger
Sandeep Nadella
Balazs Nemeth
Alice Nomura
Yongsheng Ouyang
Santanu Paul
Bernhard Renz
Marta Sandini
Heather Schofield
Matthias Sendler
Nikita Sharma
Isabelle Sheers
Masaki Sunagawa
Kazuki Takakura
Rupjyoti Talukdar
Sandra Van Brunschot
Li Wen
Min Yang
Jordan Yaron
Jun Yu
Haseeb Zubair
EXHIBITORS
The American Pancreatic Association would like to thank the following companies for providing marketing and exhibit support:

Abbvie
Akcea Therapeutics
Boston Scientific
ChiRhoClin
Cook Medical
Digestive Care
National Pancreas Foundation

Please visit our exhibitors' booths in the Grand Ballroom B Foyer

The American Pancreatic Association would like to thank Celgene for supporting Wi-Fi.

ABSTRACT SELECTION COMMITTEE
The APA Board would like to thank the following for reviewing the over 500 abstracts received:

Sulagna Banerjee - University of Miami
Howard Crawford - University of Michigan
Vikas Dudeja - University of Miami
Carlos Fernandez-del Castillo - Harvard/MGH
Toru Furukawa- Tokyo Woman’s Medical University, Japan
Pramod Garg- AIIMS, India
Guy Groblewski- UW, Madison
Anna Gukovskaya- UCLA
Aida Habtezion- Stanford University
Peter Hegyi- University of Szeged, Hungary
Joe Hines- UCLA
Karen Horvath- UW Seattle
Sohail Hussain- Children’s Hospital Pittsburgh
Myung Hwan-Kim- Asan Medical Center, Korea
Min Li- Oklahoma University
Ravikant Maddipatti- UPenn
Anirban Maitra- MD Anderson
Atsushi Masamune- Tohoku University, China
Julia Mayerle - University of Greifswald, Germany
Nipun Merchant -University of Miami
Kazuichi Okazaki - Kansai University

Marina Pasca di Magliano - University of Michigan
Nageshwar Reddy - AIG, India
Max Reichert - UPenn
Andrew Rhim - MD Anderson
Anil Rutsgi - UPenn
Miklos Sahin- Toth –Boston University
Veena Sangwan –McGill University, Canada
Kyoko Shimizu - Tokyo Women’s University, Japan
Vijay Singh – Mayo, Arizona
Vikesh Singh – Johns Hopkins
Kyoichi Takaori – Kyoto University
Masao Tanaka – Kyushu University
Margaret Tempero - UCSF
Christina Twyman-St. Victor - UPenn
Aliye Uc – University of Iowa
Huaizhi Wang – Southwest Hospital 3rd Medical University, China
Andrea Wang- Gilliam – Washington University
Christopher Wolfgang – Johns Hopkins
Bechein Wu – Kaiser Permanente
Yianjun Yu -Fudan University, China
## MEETING AT A GLANCE

### WEDNESDAY, OCTOBER 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:00 a.m. - 4:30 p.m.</td>
<td>Pre-Meeting – IPMN: Beyond Guidelines and Treatment</td>
</tr>
<tr>
<td>12:15 p.m. - 1:30 p.m.</td>
<td>Lunch</td>
</tr>
<tr>
<td>5:00 p.m. - 7:00 p.m.</td>
<td>Hirshberg Opening Symposium: Recent Advances in Pancreatic Cancer Surgery</td>
</tr>
<tr>
<td>7:00 p.m. - 9:00 p.m.</td>
<td>Presidential Reception</td>
</tr>
</tbody>
</table>

### THURSDAY, OCTOBER 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Breakfast &amp; Poster Viewing</td>
</tr>
<tr>
<td>8:30 a.m. - 10:00 a.m.</td>
<td>Abstract Session: Pancreatic Cancer</td>
</tr>
<tr>
<td>10:15 a.m. - 11:30 a.m.</td>
<td>Mini Symposium: Incidentally-discovered non-functioning neuroendocrine tumors</td>
</tr>
<tr>
<td>11:30 a.m. - 12:00 p.m.</td>
<td>Frank Brooks State of the Art Lecture</td>
</tr>
<tr>
<td>12:00 p.m. - 2:00 p.m.</td>
<td>Lunch &amp; Poster Session</td>
</tr>
<tr>
<td>2:00 p.m. - 3:05 p.m.</td>
<td>Abstract Session: Pancreatitis</td>
</tr>
<tr>
<td>3:05 p.m. - 4:20 p.m.</td>
<td>Mini Symposium: Immunobiology and Immunotherapy of Pancreatic Adenocarcinoma</td>
</tr>
<tr>
<td>4:30 p.m. - 6:45 p.m.</td>
<td>Kenner Family Research Fund Forum: Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers</td>
</tr>
<tr>
<td>7:00 p.m. - 10:00 p.m.</td>
<td>Reception &amp; Awards Dinner</td>
</tr>
</tbody>
</table>

### FRIDAY, OCTOBER 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Breakfast &amp; Poster Viewing</td>
</tr>
<tr>
<td>8:30 a.m. - 10:00 a.m.</td>
<td>Abstract Session: Pancreatitis</td>
</tr>
<tr>
<td>10:15 a.m. - 10:45 a.m.</td>
<td>Paul Webster Clinical State of the Art Lecture</td>
</tr>
<tr>
<td>10:45 a.m. - 12:00 p.m.</td>
<td>Parallel Symposium: Prevention of post ERCP pancreatitis: Stents vs Suppositories and other controversies</td>
</tr>
<tr>
<td>12:00 p.m. - 2:00 p.m.</td>
<td>Lunch &amp; Poster Session</td>
</tr>
<tr>
<td>2:00 p.m. - 2:30 p.m.</td>
<td>Business Meeting</td>
</tr>
<tr>
<td>2:30 p.m. - 3:45 p.m.</td>
<td>Mini Symposium: Multidisciplinary Management of Pancreatic Necrosis</td>
</tr>
<tr>
<td>4:00 p.m. - 5:15 p.m.</td>
<td>Mini Symposium: Novel diagnostic platforms in pancreatic cancer</td>
</tr>
<tr>
<td>5:15 p.m. - 6:30 p.m.</td>
<td>Parallel Sessions: Clinical Science Abstracts</td>
</tr>
<tr>
<td>7:00 p.m.</td>
<td>Women in Pancreas Reception &amp; Dinner</td>
</tr>
</tbody>
</table>

### SATURDAY, OCTOBER 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Abstract Session: Pancreatic Cancer</td>
</tr>
<tr>
<td>10:00 a.m. - 10:30 a.m.</td>
<td>Mini Symposium: Update on NIH Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)</td>
</tr>
<tr>
<td>10:45 a.m. - 12:00 p.m.</td>
<td>Mini Symposium: Regeneration, inflammation and cancer</td>
</tr>
<tr>
<td>12:00 p.m. - 1:15 p.m.</td>
<td>Mini Symposium: PanCan Young Investigators</td>
</tr>
</tbody>
</table>
ONSITE REGISTRATION HOURS
Location | Exeter Foyer
Wednesday, 10/26  7am – 7pm
Thursday, 10/27    7am – 6pm
Friday, 10/28      7am – 6:30pm
Saturday, 10/29    7am – 1:15pm

SOCIAL EVENTS

PRESIDENTIAL RECEPTION
Wednesday, October 26 | 7:00 pm – 9:00 pm  Location | Georgina ABC
The Presidential Reception is held in honor of APA President Carlos Fernandez-del Castillo.

AWARDS DINNER & RECEPTION
Thursday, October 27 | 7:00 pm – 10:00 pm
Reception 7:00 pm – 8:00 pm  Location | Georgian ABC
Dinner 8:00 pm – 10:00 pm  Location | Grand Ballroom A
The following awards will be presented: Hirshberg Foundation and National Pancreas Foundation Awards for Best abstracts in Pancreatitis and Pancreatic Cancer, the Distinguished Service and the Vay Liang & Frisca Go Award for Lifetime Achievement along with felicitation of Young Investigators awardees.

WOMEN IN PAREAS RECEPTION & DINNER
Friday, October 28, 7:00 pm
Reception Location | Arlington Berkeley Clarendon
Dinner Location | Georgian
All women registered are invited to attend this event. RSVPs are requested; contact the reservation desk. Keynote Speakers: Stephen Blattner, MD, MBA and Judith Simmons, MD, from exāgoMD, LLC and Jacqueline Rosenthal from ZurickDavis.

APA FOUNDATION
The APA Foundation was officially launched three years ago with the purpose of providing education, research, and charitable support to the APA mission and initiatives. Our society continues to provide a forum for communications and support for young investigators to present their outstanding research work in pancreatic diseases. Our society is now celebrating its 47th annual meeting this year. Our foundation has an excellent start in creating an endowment fund. Thank you to the Board of Directors and the APA members whose generosity has contributed to our foundation. The future of our society and its mission is in our own hands.

Please send your contributions to the APA Foundation:
11411 Four Fillies Road
Pinecrest, FL 33156

The Board of Directors, Steve Pandol MD, Ashok Saluja MD, Edward Bradley MD, William Chey MD, Edward D. Purich PhD, Agi Hirshberg, Barbara Kenner PhD, Peter Banks MD, Howard Reber MD, Andrew Warshaw MD, Paul Webster MD, and Vay Liang Go MD, Chair, would like to express our heartfelt gratitude for your support.
DISTINGUISHED SERVICE AWARD

SUDHIR SRIVASTAVA, PH.D., MPH, MS

Dr. Srivastava is Senior Scientific Officer and Chief of the Cancer Biomarkers Research Group in the Division of Cancer Prevention, National Cancer Institute. He joined the National Cancer Institute in 1988. Since 1990, he has served as program director in the Division of Cancer Prevention and focused his responsibility in developing molecular signatures of cancer cells for cancer detection research programs with primary emphasis on cancer screening, early detection, risk assessment and informatics.

Dr. Srivastava is an internationally recognized leader in cancer biomarker research. He is best known for his seminal contributions to improving systems approach to biomarker discovery, development and validation. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network (EDRN; http://www.cancer.gov/edrn), a flagship program at the National Cancer Institute, National Institutes of Health. Under his leadership the network has begun translating biomarkers into clinical tests for early detection and diagnosis, risk assessment, and prognosis. He has spearheaded the role of chemical sciences in oncology by establishing the NCI's Alliance of Glycobiologists (glycomics.cancer.gov) to study the structure-function relationship of glycans and biomarkers in cancer detection and diagnosis. He has played a key role in conceptualizing and implementing informatics infrastructure for the EDRN in collaboration with NASA (Jet Propulsion Laboratory), a model collaboration being followed elsewhere in NIH. For his creativity, he received a JPL Group Achievement Award in 2011.

Dr. Srivastava is best known for his work on developing medical guidelines on the diagnosis of Hereditary Non-polyposis Colorectal Cancer (HNPCC). He played a pivotal role in the development of the Bethesda Guidelines for diagnosing HNPPC, which is in clinical practice world-wide. He has received several honors and awards and is a member of a number of scientific committees world-wide. In 1995, he was elected to the American Joint Committee on Cancer (AJCC) which is responsible for developing staging criteria for cancers for worldwide use and currently serves on the AJCC Executive Committee. He has been a visiting Professor at several medical and academic institutions, and has delivered several inaugural and keynote addresses.

He is the founding Editor-in Chief of the journal Cancer Biomarkers, and was the editor of Disease Markers (2002-2013) published by the IOS press and serves as Associate Editors and reviewers for several internally know journals. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. He has edited several monographs and edited five books.

In 2016, he received a Cancer Prevention Distinguished Alumni Award for his accomplishments and mentoring of fellows. He was featured in Wired magazine in August 2003 for his leadership in cancer diagnostics. He has been planning and managing comprehensive extramural scientific programs for more than 26 years. This year, he was also invited to brief the US Congress on progress made on biomarkers for cancer early detection. He has successfully managed several mission-critical goals of the National Cancer Institute at various fronts including: conceptual, infrastructure, dependency linkage, and coordination among various federal, academic and private sector constituents. For these activities, he has received numerous NIH Director Awards and NIH Merit Awards.

Dr. Srivastava received his PhD. Degree in biological science from Banaras Hindu University in 1977. Subsequently, he received his M.S. degree in Computer Science from the Virginia Commonwealth University in 1987 and a MPH degree from the Johns Hopkins University in 1997. He did postdoctoral work at the University of Osaka, Japan; the University of California at San Francisco; and the University of Arizona, Tucson.
CHRIS E. FORSMARK, MD

Dr. Chris Forsmark was born and raised in Colorado, growing up in the mountains near Granby before his family moved to Denver. His mother, a schoolteacher, and his father, a bookkeeper, were both exceedingly well read and instilled an appreciation of hard work and self-improvement. He developed an interest in medicine while a high school student and graduated from the University of Colorado, Boulder, with a degree in chemical engineering, and then attended medical school at Johns Hopkins. During training at Hopkins, he developed an interest in gastrointestinal and liver diseases due to the impressive number of outstanding faculty and trainees. He received the Warfield Longcope prize (best student in internal medicine), along with election to Phi Beta Kappa and Alpha Omega Alpha at graduation. He moved to the University of California, San Francisco for internal medicine training, chief residency, and GI fellowship. It was here that he became specifically interested in pancreatic diseases, due to mentorship and inspiration from Jim Grendell, John Cello, and Roger Liddle. It was also here that he developed life-long connections with others interested in the pancreas and fibrosis including Mel Wilcox, Scott Friedman, and Brent Neuschwander-Tetri.

Dr. Forsmark joined the faculty of the University of Florida in 1990, choosing this institution due to mentorship from Phil Toskes who has been attending the APA meetings since 1991. Although much of his activity related to advanced endoscopy, Dr. Toskes proved instrumental in helping him develop an understanding of medical pancreatology, pancreatic physiology, and the ingredients necessary for a successful academic and clinical research career. Dr. Forsmark became a tenured professor at UF in 2003. He served as the Director of Endoscopy and subsequently the Chief of the Division of Gastroenterology, Hepatology, and Nutrition of the University of Florida. He also served as Chair of the AGA Pancreas Section, President of the Florida Gastroenterologic Society, and Chair of the ABIM Gastroenterology Board. He is the former Associate Editor for Pancreas for the American Journal of Gastroenterology, and on the editorial board of several journals including Pancreas and Pancreatology. He serves as a board member for the National Pancreas Foundation. He is perhaps most proud of the opportunity to serve as President of the APA in 2006, organizing a combined APA-IAP meeting.

Dr. Forsmark is at heart a clinician, involved in both the medical management and endoscopic management of many patients with acute and chronic pancreatitis and with pancreatic malignancies. In conjunction with Phil Toskes, a rather unique training program combining advanced endoscopy and medical pancreatolology was created at UF, which now has numerous graduates. Much of his research has focused on issues that combine the endoscopic and medical approaches to these patients, and in particular methods of early diagnosis of chronic pancreatitis. He is the author of more than 90 peer-reviewed publications, numerous book chapters, and multiple reviews and editorials. Most recently, he and his colleagues at UF participate in the NIDDK/NCI UO-1 consortium to study chronic pancreatitis, diabetes, and pancreatic cancer. This 5-10 year project will attempt to delineate the intricate and tri-directional relationships between these diseases, with a goal of more accurate diagnosis, more effective therapy, and earlier detection. Dr Forsmark and Dr Steven Pandol chair this UO-1 consortium.

Dr. Forsmark wishes to express his gratitude to the APA for the tremendous honor of the Go Lifetime Achievement Award, and to Bill and Frisca Go for their generosity. He feels there are so many people who are equally deserving of recognition within the APA. He is especially thankful for the advice and guidance provided by leaders in the APA, including Bill Go, Ashok Saluja, Howard Reber, Ed Bradley, Roger Liddle, Phil Toskes, Raul Urrutia, and so many others. He would also like to acknowledge and thank his wife Rusty, who for 36 years has provided support, counsel and love, and his 2 (outstanding) daughters Kate and Britta.
IPMN: BEYOND GUIDELINES AND TREATMENT
Pre-Meeting Directors | Carlos Fernandez-del Castillo and Anirban Maitra

APA PRE-MEETING | Boston 2016
Wednesday, October 26
Grand Ballroom A

7:00 – 8:00am
Breakfast
Location | Georgian

8:00 – 9:00am
Biology of IPMN: Insights through bench research
Leader | Nabeel Bardeesy, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School
Maximilian Reichert, MD, Technical University of Munich
*Investigating the Molecular Origin of Pancreatic Cystic Neoplasm to Develop Targeted Therapies*
Nilotpal Roy, PhD, University of California, San Francisco
*The role of SWI/SNF chromatin remodeling complex in IPMN-derived PDAC*

9:00 – 10:00am
Pathology of IPMN: The value of classification and sub classification
Leader | Mari Mino-Kenudson, MD
Toru Furukawa, MD, PhD, Tokyo Women’s Medical University
*Subtype classification of IPMN and its impact on patient care*
Olca Basturk, MD, Memorial Sloan Kettering Cancer Center
*Implications of minimally-invasive IPMN*

10:00 – 10:15am
Break
Location | Grand Ballroom B Foyer

10:15 – 11:15am
Molecular pathology of IPMN: Genes and expression explain transformation
Leader | Anirban Maitra, MBBS
Michael Goggins, MD, Johns Hopkins University
*Molecular Genetics of IPMN*
Jens Siveke, MD, University Hospital Essen
*The Role of Epigenetic Alterations in IPMN development*
11:15 – 12:15pm  **Clinical dilemmas in IPMN: Are we over treating a disease?**  
Leader | Timothy Gardner, MD, MS  
Suresh T. Chari, MD, Mayo Clinic College of Medicine  
*Most incidentally discovered pancreatic cysts are innocuous and do not need resection*  
Christopher Wolfgang, MD, MS, PhD, Johns Hopkins University  
*IPMNs have malignant potential and close surveillance is needed for those patients*

12:15 – 1:30pm  **Lunch**  
Location | Georgian AB

1:30 – 2:30pm  **Cyst fluid analysis in IPMN: Diagnosis and identification of high-risk lesions**  
Leader | Annemarie Lennon, MD, PhD  
Peter Allen, MD, FACS, Memorial Sloan Kettering Cancer Center  
*A panel of inflammatory markers distinguishes low from high-grade IPMNs*  
Nickolas Papadopoulos, PhD, Johns Hopkins, Sidney Kimmel CCC, Ludwig Center  
*Identification of genetic mutations in the fluid of IPMNs*  
Martha Bishop Pitman, MD, Massachusetts General Hospital/ Harvard Medical School  
*The value of fluid cytology in triaging IPMN*

2:30 – 3:30pm  **State of the art imaging in IPMN**  
Leader | Dushyant V. Sahani, MD  
William R. Brugge, MD, Massachusetts General Hospital  
*Innovations in Endoscopic Ultrasound*  
Koenraad J. Mortele, MD, Beth Israel Deaconess Medical Center  
*Recent advances in MRI and MRCP*

3:30 – 4:30pm  **Present and future challenges in IPMN**  
Panel Discussion Moderator | Carlos Fernandez-del Castillo, MD  
Participants  
Masao Tanaka, MD, PhD, FACS, Kyushu University, Japan  
Philippe Levy, PhD, Hopital Beaujon APHP, Clichy, France  
Jin-Young Jang, MD, PhD, Seoul National University  
Santhi S. Vege, MD, Mayo Clinic, Rochester  
Thilo Hackert, MD, University of Heidelberg, Germany  
Claudio Bassi, MD, Pancreas Institute Verona, Italy  
Tooru Shimosegawa MD, PhD, Tohoku University Graduate School of Medicine
THE AMERICAN PANCREATIC ASSOCIATION’S
47th Annual Meeting

WEDNESDAY, October 26
Grand Ballroom A

5:00 – 7:00 pm  Hirshberg Symposium: Recent Advances in Pancreatic Cancer Surgery
Moderator | Carlos Fernandez-del Castillo, MD and Ashok K. Saluja, PhD

Oscar Joe Hines, MD, David Geffen School of Medicine at UCLA
*Three decades of progress in pancreatic surgery: safer and more standardized operations*

Michael L. Kendrick, MD, Mayo Clinic Rochester
*Emergence and role of minimally invasive surgery for pancreatic cancer*

Cristina R. Ferrone, MD, MGH, Harvard Medical School
*Modern neoadjuvant therapy downstages pancreatic cancer and increases candidates for surgery*

Thilo Hackert, MD, University of Heidelberg, Germany
*Crossing to new frontiers: surgery for recurrent and metastatic pancreatic cancer*

7:00 – 9:00 pm  Presidential Reception
Location | Georgian ABC

THURSDAY, October 27
Grand Ballroom A

7:00 – 8:30 am  Breakfast & Poster Viewing
Breakfast
Location | Georgian ABC

Meet the Professor Breakfast | Georgian ABC

Poster Viewing
Location | Grand Ballroom B and Statler

8:30 – 10:00 am  Pancreatic Cancer Abstract Session
Location | Grand Ballroom A
Moderators | Min Li, PhD and Guido Eibl, MD
A New Mouse Model Demonstrates the Necessity of Mutant P53 Expression for Pancreatic Cancer Progression
H. Schofield¹, J. Zeller¹, A.E. Cali Daylan², C. Kumar¹, E. Fearon¹, M. Pasca Di Magliano¹
¹University of Michigan/USA, ²Hacettepe University Medical School/Turkey

Pancreatic Microtumors: A Novel Platform for Screening Chemotherapeutic Agents
M. Goodwin, S. Urs, Z. Sila, D. Simeone
Surgery, University of Michigan, Ann Arbor, MI/USA

NFκB in Tumor Stroma Modulates Cancer Growth in Mouse Models of Pancreatic Cancer
Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, USA

IL-6 and Pd-L1 Antibody Blockade Combination Therapy Limits Tumor Progression in Murine Models of Pancreatic Cancer
T. Mace¹, R. Shakya¹, J.R. Pitaresi¹, B. Swanson¹, C. McQuinn¹, S. Loftus¹, L. Yu¹, G. Young¹, X. Zhong², T. Zimmers², M. Ostrowski¹, T. Ludwig¹, M. Dillhoff², C. Schmidt¹, D. Conwell¹, T. Bekaii-Saab³, G. Lesinski¹
¹The Ohio State University/USA, ²Indiana University/USA, ³Mayo Clinic/USA

Espac-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (Gem) and Capecitabine (Cap), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma
J.P. Neoptolemos¹, D. Palmer¹, P. Ghanéi¹, J. Valle², D. Cunningham³, J. Wadsley⁴, T. Meyer⁵, A. Anthoney⁶, B. Glimelius⁷, S. Falk⁸, P. Lind⁹, J. Izbički¹⁰, G. Middleton¹¹, P. Rossi¹², H. Wasan¹³, A. McDonald¹⁴, T. Crosby¹⁵, E. Psarelli¹, P. Hammel¹⁶, M.W. Büchler¹⁷
¹University of Liverpool, Liverpool/United Kingdom, ²University of Manchester & The Christie, Manchester/United Kingdom, ³Royal Marsden Hospital, London/United Kingdom, ⁴Weston Park Hospital, Sheffield/United Kingdom, ⁵Royal Free Hospital, London/United Kingdom, ⁶St James's University Hospital, Leeds/United Kingdom, ⁷University of Uppsala, Uppsala/Sweden, ⁸Bristol Hematology and Oncology Centre, Bristol/United Kingdom, ⁹Karolinska University Hospital, Stockholm/Sweden, ¹⁰University of Hamburg Medical Institutions UKE, Hamburg/Germany, ¹¹Royal Surrey County Hospital, Guildford/United Kingdom, ¹²Guy's Hospital, London/United Kingdom, ¹³Hammersmith Hospital, London/United Kingdom, ¹⁴The Beatson West of Scotland Cancer Centre, Glasgow/United Kingdom, ¹⁵Velindre Hospital, Cardiff/United Kingdom, ¹⁶Hôpital Beaujon, Clichy/France, ¹⁷University of Heidelberg, Heidelberg/Germany

Alternative Lengthening Of Telomeres and Loss of Daxx/Atrx Expression Predicts Metastatic Disease and Poor Survival in Patients With Pancreatic Neuroendocrine Tumors
A.D. Singhi¹, T.-C. Liu², J.L. Roncaioli³, H.J. Zeh⁴, A.H. Zureikat⁴, A. Tsung⁵, J.W. Marsh⁶, K.K. Lee⁷, M.E. Hogg⁸, N. Bahary⁹, R.E. Brand⁵, K. McGrath⁵, A. Slivka², K.L. Cressman¹, K. Fuhler¹, R.J. O'Sullivan³
¹Department of Pathology, University of Pittsburgh Medical Center, PA/USA, ²Department of Pathology, Washington University, MN/USA, ³Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA/USA, ⁴Department of Surgery, University of Pittsburgh Medical Center, PA/USA, ⁵Department of Medicine, University of Pittsburgh Medical Center, PA/USA
Digital Next-Generation Sequencing Identifies Low-Abundance Mutations in Pancreatic Juice Samples of Patients With Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms

J. Yu¹, Y. Sadakari¹, K. Shindo¹, M. Suenaga¹, A. Brant¹, J.A.N. Almario¹, M. Borges¹, T. Barkley¹, S. Fesharakizadeh¹, M. Ford¹, R.H. Hruban¹,2, E.J. Shin¹, A.M. Lennon²,4, M.I. Canto²,³, M. Goggins¹,²,³

¹Pathology department, The Johns Hopkins University, MD/United States of America, ²Medicine department, The Johns Hopkins University, MD/United States of America, ³Oncology department, The Johns Hopkins University, MD/United States of America, ⁴Surgery department, The Johns Hopkins University, MD/United States of America

10:00 – 10:15am
Break
Location | Grand Ballroom B Pre-function

10:15 – 11:30am
MINI SYMPOSIUM: Incidentally-discovered non-functioning neuroendocrine tumors
Location | Grand Ballroom A
Moderators | Cristina Ferrone, MD and Massimo Falconi, MD

Massimo Falconi, MD, San Raffaele Hospital, Milan

The natural history of non-functioning PNETs

Peter Allen, MD, FACS, Memorial Sloan Kettering Cancer Center
Most patients with incidentally discovered PNETs can be managed non-operatively

Tetsuhide Ito, MD, PhD, Kyushu University, Japan
Management of non-functioning PNETs in Japan

Christopher Wolfgang, MD, MS, PhD, Johns Hopkins University
Size and risk of lymph node metastases in non-functioning PNETs

11:30-12:00 pm
Frank Brooks State of the Art Lecture (Basic Science)
Location | Grand Ballroom A
Introduction | Ashok K. Saluja, PhD

Craig Logsdon, PhD, MD Anderson
The stressed acinar cell: Adapt, die or disaster

12:00 – 2:00 pm
Lunch & Poster Session
Lunch | Georgian ABC

Poster Session
Location | Grand Ballroom B and Statler
Guided viewing of the posters of distinction – 1-2pm
Lead by | Murray Korc, MD and Minoti V. Apte, MBBS, PhD
Fred S. Gorelick, MD and Johanna Laukkarinen, MD, PhD
Meet at Registration / Location | Exeter Foyer

2:00 – 3:05pm
Pancreatitis Abstract Session
Location | Grand Ballroom A
Moderators | Guy E. Groblewski, PhD and Anna Gukovskaya, PhD
Downregulation of Atg4b Stimulates Autophagy and Ameliorates Alcohol-Induced Pancreatic Injury
J.M. Elperin1, S. Suriany1, G.E. Lee1, S.W. French2, A.S. Gukovskaya1, I. Gukovsky1, O.A. Mareninova1
1Veterans Affairs Greater Los Angeles Healthcare System and University of California at Los Angeles/United States of America, 2Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA/United States of America

Genetic Deletion of Ampk Results in Greater Baseline and Secretagogue-Stimulated Enzyme Activity and Cellular Injury
C.A. Shugrue1, A.J. Ceplenski1, E.J. Foglio2, V. Patel1, M. Foretz3, B. Viollet3, F.S. Gorelick4
1Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT/United States of America, 2Department of Pediatrics, Yale University School of Medicine, New Haven, CT/United States of America, 3Institut Cochin, INSERM, Paris/France, 4VA Connecticut Healthcare, West Haven, CT/United States of America

Epithelial Cell-Specific Calcineurin Signaling Mediates Inflammation in the Context of Pancreatitis
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA/United States of America

Endoscopic or Surgical Step-Up Approach for Necrotizing Pancreatitis, a Multi-Center Randomized Controlled Trial
S. Van Brunschot
On behalf of the Dutch Pancreatitis Study Group/Netherlands

Tissue Immunohistochemistry Differentiates Diabetic Exocrine Pancreatopathy From Chronic Pancreatitis
S. Majumder1, N.A. Philip1, Y. Zen2, L. Zhang1, R.P. Sah1, W.S. Harmsen1, F.T. Enders1, T.C. Smyrk3, S.T. Chari1
1Mayo Clinic/United States of America, 2Kobe University/Japan, 3Laboratory Medicine & Pathology, Mayo Clinic/United States of America

Effect of Intrapancreatic Fat on Diabetes Risk After Total Pancreatectomy With Islet Autotransplantation
M. Kizilgul1, M. Bellin1,2, M. Abdulla1, D. Heller1, G.J. Beilman3, S. Chinnakotla1, T.B. Dunn2, T.L. Pruitt1, B.J. Hering1, J.J. Wilhelm1
1Schulze Diabetes Institute, University of Minnesota/United States of America, 2Department of Pediatrics, University of Minnesota, Minneapolis, MN/United States of America, 3Surgery, University of Minnesota, Minneapolis, MN/United States of America

MINI SYMPOSIUM: Immunobiology and Immunotherapy of Pancreatic Adenocarcinoma
Location | Grand Ballroom A
Moderator | Kyoichi Takaori, MD, PhD and Margaret A. Tempero, MD

George Miller, MD, New York University
Unraveling the Immunobiology of Pancreatic Cancer

David Linehan, MD, University of Rochester Medical Center
CCR2: A new immune target for Pancreatic Cancer
Margaret A. Tempero, MD, University of California San Francisco

Integrating Immunotherapy into Pancreatic Cancer Treatment: Lessons from a SU2C Team

4:20 – 4:30pm  Break
Location | Terrace Foyer

4:30 – 6:45pm  Kenner Family Research Fund Forum: Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers
Location | Terrace

Barbara Kenner, PhD, Kenner Family Research Fund

Forum Overview

Sudhir Srivastava, PhD, MPH
Chief, Cancer Biomarkers Research Group
National Cancer Institute

Current State of Biomarkers

Anne-Renee Hartman, MD,
Medical Director and Director of Clinical Product Development
GRAIL

Christer Wingren, PhD
Chief Technology Officer
Laura Chirica, PhD
Chief Commercial Officer
Immunovia

Niven R. Nirain, MD
Co-Founder, President, and CEO of Berg
A. James Moser, MD, FACS
Co-Director, Pancreas and Liver Institute
Beth Israel Deaconess Medical Center
Project Survival

Suresh T. Chari, MD, Mayo Clinic College of Medicine
Stephen J. Pandol, MD, Cedars-Sinai Medical Center

Discussion and Analysis

7:00 – 10:00pm  Awards Dinner & Reception

Reception 7:00 – 8:00 pm
Location | Georgian ABC
Dinner 8:00 – 10:00 pm
Location | Grand Ballroom A
FRIDAY, October 28
Grand Ballroom A

7:00 – 8:30am  Breakfast & Poster Viewing

Breakfast
Location | Georgian ABC

Meet the Professor Breakfast
Location | Georgian ABC

Poster Viewing
Location | Grand Ballroom B and Statler

8:30 – 10:00am  Pancreatitis Abstract Session
Location | Grand Ballroom A
Moderators | Vikas Dudeja, MD and Kazuichi Okazaki, MD, PhD

Investigating the Novel Function of Hippo Signaling in Pancreatic Acinar Cells
M. Gao1, J. Liu1, J. Leighton1, X. Yin1, R.L. Johnson2, P. Wang1
1Department of Cellular and Structural Biology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, 2Department of Cancer Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston/United States of America

Glycogen Synthase Kinase-3beta Ablation Limits Pancreatitis Induced Acinar-To-Ductal Metaplasia
L. Ding1, G.-Y. Liou2, J.-S. Zhang1, P. Storz2, D.D. Billadeau1
1Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN/United States of America, 2Department of Cancer Biology, Mayo Clinic, Jacksonville, FL/United States of America

Therapeutic Adam 10 And 17 Inhibition Reduces Local and Systemic Inflammation in Acute Pancreatitis
J. George1, A. Dixit1, A. Sarcen2, H. Cheema1, B. Giri1, V. Dudeja1, R. Dawra1, A.K. Saluja1
1 Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America, 2Surgery, University of Minnesota, United States of America

Small Molecule CCR2 Antagonist Therapy in Experimental Model of Chronic Pancreatitis
J. Xue1**, Q. Zhao1*, V. Sharma1, J. Kalisiak2, Y. Zeng2, A. Krasinski2, P. Zhang2, J. McMahon2, J. Campbell3, I. Charo2, T. Schall2, A. Habtezion1
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA, 2ChemoCentryx, Mountain View, CA 94043, USA, *Renji-MedX Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China, **Contributed equally

Cholecystectomy (Ccy) During Index Admission for Acute Pancreatitis (Ap) Decreases the Risk of Recurrences and Readmissions: A National-Level Analysis
S.G. Krishna1, A. Hinton1, D. Yadav2, D. Conwell1
1Ohio State University Medical Center, Columbus, OH/United States of America, 2University of Pittsburgh Medical Center/United States of America
Minimally Invasive Versus Open Necrosectomy for Necrotizing Pancreatitis
1Surgery, Academic Medical Center Amsterdam/Netherlands, 2Gastroenterology, Academic Medical Center Amsterdam/Netherlands, 3Surgery, University Medical Center Utrecht/Netherlands, 4Gastroenterology and Hepatology, University of North Carolina, NC/United States of America, 5Surgery, University of Ulm/Germany, 6Radiology, St. Antonius Hospital/Netherlands, 7Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam/Netherlands, 8Glasgow Royal Infirmary/United Kingdom, 9Department of HPB Surgery, Newcastle upon Tyne Hospitals, Newcastle Upon Tyne/United Kingdom, 10Hospital Clementino Fraga Filho, Rio De Janeiro/Brazil, 11Of Internal Medicine, Oldenburg Municipal Hospital, Oldenburg/Germany, 12Clinical Research Unit, Academic Medical Center, Amsterdam/Netherlands, 13Surgery, Jaslok Hospital and Research Center/India, 14University of Szeged, Szeged/Hungary, 15Massachusetts General Hospital, Boston/United States of America, 16Department of Surgery, Massachusetts General Hospital, MA/United States of America, 17Academic Medical Center Amsterdam/Netherlands, 18Gastroenterology, University of Minnesota, Minneapolis/United States of America, 19Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center/United States of America, 20Surgery, Radboud University Medical Center/Netherlands, 21Operating Rooms - Evidence Based Surgery, Radboud University Medical Center, Nijmegen/Netherlands, 22Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen/Netherlands, 23Surgery, Freeman Hospital, Newcastle Upon Tyne/United Kingdom, 24Surgery, Glasgow Royal Infirmary, Glasgow/United Kingdom, 25Surgery, Massachusetts General Hospital, Boston/United States of America, 26National Institutes of Health Research Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospitals, Liverpool/United Kingdom, 27Surgery, Petz-Aladár teaching hospital, Győr/Hungary, 28Surgery, University of Edinburgh, Edinburgh/United Kingdom, 29Surgery, Royal Liverpool and Broadgreen University Hospitals, Liverpool/United Kingdom, 30Surgery, University of Rostock, Rostock/Germany, 31Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg/Germany, 32Internal Medicine, Oldenburg Municipal Hospital, Oldenburg/Germany, 33Surgery, Manchester Royal Infirmary, Manchester/United Kingdom, 34Surgery, University of Washington, Seattle/United States of America, 35Surgery, St. Antonius Hospital, Nieuwegein/Netherlands

Role of Chymotrypsin C in Cerulein-Induced Pancreatitis in the Mouse
Z. Jancso, A. Geisz, B.C. Nemeth, M. Sahin-Toth
Boston University, Boston/United States of America

10:00 – 10:15am Break
Location | Grand Ballroom B Pre-function

10:15 - 10:45am Paul Webster Clinical Start of Art Lecture
Location | Grand Ballroom A
Introduction | Carlos Fernandez-del Castillo, MD
David Patrick Ryan, MD, Harvard Medical School

*Pancreatic Cancer in 2017: Where are we and where are we heading?*

10:45 - 12:00pm

**Parallel Session: Prevention of post ERCP pancreatitis: Stents vs Suppositories and other controversies**

Location | *Grand Ballroom A*
Moderators | Martin L. Freeman, MD and Nageshwar Reddy, MD

Martin L. Freeman, MD, University of Minnesota
*Case Presentation*

Sohail Husain, MD, Children's Hospital of Pittsburgh of UPMC
*Probing the Mechanisms Underlying Post-ERCP Pancreatitis*

Shyam Varadarajulu, MD, Florida Hospital Center for Interventional Endoscopy
*Pancreatic stents are paramount, NSAIDs a nuisance*

Jamie Barkin, MD, MACP, MACG, University of Miami Miller School of Medicine
*NSAIDS are necessary, pancreatic stents peripheral*

Gregory Cote, MD, Medical University of South Carolina
*The truth is somewhere in the middle*

Martin Freeman, MD, University of Minnesota
*Case Presentation*

Panel Debate

10:45 - 12:00pm

**Parallel Session: What Matters in Pancreatitis**

Location | *Terrace*
Moderators | Aida Habtezion, MD, MSc and Julia Mayerle, MD

Miklos Sahin-Toth, MD, PhD, Boston University School of Medicine
*In chronic pancreatitis it’s all genetics!*

Pramod Garg, MD, All India Institute of Medical Sciences
*In chronic pancreatitis it’s all environment*

Markus M. Lerch, MD, University Medicine Greifswald, Germany
*In acute pancreatitis it’s all genetics*

Vijay P. Singh, MBBS, Mayo Clinic
*In acute pancreatitis it’s all environment*

12:00 – 2:00 pm

**Lunch & Poster Session**

Lunch
Location | *Georgian ABC*

Poster Session
Location | *Grand Ballroom B and Statler*
Guided viewing of the posters of distinction – 1-2pm
Lead by | Rodger Liddle, MD and Jill Palmer Smith, MD, PhD
        Dana K. Andersen, MD and Robert Sutton, MB, BS, FRCS, DPhil
Meet at Registration / Location | Exeter Foyer

2:00 - 2:30pm

**Business Meeting**
Location | Grand Ballroom A

**Presidential Address** Carlos Fernandez-del Castillo, MD
**Secretary-Treasurer's Report** Ashok K. Saluja, PhD

**Report from the Nominating Committee** Carlos Fernandez-del Castillo, MD

2:30 - 3:45pm

**MINI SYMPOSIUM: Multidisciplinary Management of Pancreatic Necrosis**
Location | Grand Ballroom A
Moderators | Peter A. Banks, MD & Julia McNabb- Baltar, MD, MPH

Julia McNabb-Baltar, MD, MPH, Brigham and Women’s Hospital, Boston
*Case Presentation*

Vikesh Singh, MD, MSc, Johns Hopkins University School of Medicine
*The Epidemiology of and Risk Factors for Pancreatic Necrosis*

Koenraad J. Mortele, MD, Beth Israel Deaconess Medical Center
*Radiologic Imaging Standards*

Christopher C. Thompson, MD, Brigham and Women’s Hospital, Boston
*Update on Endoscopic Management*

Peter J. Fagenholz, MD, Massachusetts General Hospital
*Minimally Invasive Surgery Approaches*

Bechien U. Wu, MD, Kaiser Permanente
*State of Art: Pancreatic Necrosis - A Multidisciplinary Approach to Management*

Panel Discussion: Moderators - all speakers

3:45 – 4:00pm

Break
Location | Grand Ballroom B Pre-function

4:00 - 5:15pm

**MINI SYMPOSIUM: Novel diagnostic platforms in pancreatic cancer**
Location | Grand Ballroom A
Moderators | Andrew D. Rhim, MD and Maximilian Reichert, MD

David T. Ting, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School
*Pancreatic cancer circulating tumor cells*

Andrew D. Rhim, MD, MD Anderson Cancer Center
*Ultrasensitive approaches to mutation detection in liquid biopsies*

Surinder K. Batra, PhD, University of Nebraska Medical Center
*Serum microRNAs in pancreatic cancer*
5:15 - 6:30pm

Parallel Session: (Clinical Science Abstracts)
Location | Grand Ballroom A
Moderators | Yi Miao, MD and Jens Werner, MD, MBA

Elevated Circulating Histones Associate With Multiple Organ Dysfunction Syndromes in Acute Pancreatitis

1Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool/United Kingdom, 2NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, 3Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University/China, 4Intensive Care Unit, Royal Liverpool University Hospital, Liverpool/United Kingdom, 5Roald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool University Hospital/United Kingdom

Autoimmune Pancreatitis in Children: Working Guidelines for Diagnosis and Management

1Hospital for Sick Children, Toronto/Canada, 2Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, 3Harvard Medical School, Beth Israel Deaconess Medical Center, Boston/United States of America, 4Hadassah Hebrew University Hospital, Jerusalem/Israel, 5Harvard Medical School, Massachusetts General Hospital for Children, Boston/United States of America, 6University of Texas Southwestern Medical School, Dallas/United States of America, 7Baylor College of Medicine, Houston/United States of America, 8Nationwide Children’s hospital, Columbus/United States of America, 9Seattle Children's Hospital, Seattle/United States of America, 10University of California at San Francisco, San Francisco/United States of America, 11Children's Hospital of Pittsburgh of UPMC, Pittsburgh/United States of America, 12Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles, Los Angeles/United States of America, 13The Children's Hospital of Philadelphia, Philadelphia/United States of America, 14Montreal Children’s Hospital, McGill University, Montreal/Canada, 15Discipline of Pediatrics, School of Women’s and Children’s Health, Medicine, University of New South Wales and Sydney Children’s Hospital Randwick, Sydney/Australia, 16University of Utah, Salt Lake City/United States of America, 17University of Minnesota Masonic Children’s Hospital, Minneapolis/United States of America, 18Medical College of Wisconsin, Milwaukee/United States of America, 19University of Iowa Carver College of Medicine, Iowa City/United States of America

Progression of Acute Pancreatitis to Acute Recurrent Pancreatitis in the Pediatric Population: A Single Center Prospective Database Report

Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America
Pancreatic Mucinous Cystic Neoplasms (Mcn) Of Any Size, Without Worrisome Features or Symptoms Can Be Safely Surveyed In Women but Should Be Resected In Men: A Multinational Cohort Study Including 211 Patients
G. Keane1, A. Shamili2, L. Nilsson3, A. Antila4, J.B. Millastre5, M.V.Z. Monica6, C. Verdejo7, Y. Vaalavuo8, T. Hoskins8, S. Robinson8, G. Ceyhan9, M. Abuhilal10, S. Pereira11, J. Laukariainen11, M. Del Chiaro11
1Institute for Liver and Digestive Health, University College London, United Kingdom, 2Southampton University Hospital/United Kingdom, 3Karolinska Institute/Sweden, 4Tampere University Hospital/Finland, 5Gastroenterology, Miguel Servet University Hospital/Spain, 6Pathology, Nijmegen University Hospital/Netherlands, 7GASTROENTEROLOGY, HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL/Spain, 8Freeman Hospital, Newcastle/United Kingdom, 9Technische Universität München/Germany, 10Southampton University Hospital, United Kingdom/United Kingdom, 11Institute for Liver and Digestive Health, University College London United Kingdom Freeman Hospital, Newcastle/United Kingdom, 12Div. of Surgery, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm/Sweden

DNA Analysis of Pancreatic Cystic Fluid Has Incremental Predictive Value in Assessing Future Risk of Malignant Outcomes
J.J. Farrell1, S. Jackson2, N. Toney2, T. Gonda3
1Yale Center for Pancreatic Disease, Yale University, New Haven, CT/United States of America, 2Clinical Development, Interpace Diagnostics Corporation, Pittsburgh, PA/United States of America, 3Division of Digestive and Liver Disease, Columbia University, New York, NY/United States of America

Risk for Pancreatic Cancer in Patients With Pancreatic Cysts and Family History of Pancreatic Cancer
A. Sharma, S. Mukewar, N. Philip, S.S. Vege, S.T. Chari
Gastroenterology and Hepatology, Mayo Clinic, MN/United States of America

Parallel Session: (Basic Science Abstracts)
Location | Terrace
Moderators | Aliye Uc, MD and Aditi Bhargava, PhD

Exosome-Mediated Communication Between Pancreatic Carcinoma Cells and Pancreatic Stellate Cells Is Ca2+ Regulated and Dependent on the Snare- And Ca2+-Binding Protein, Munc13-4
S. Messenger1, T. Martin2
1Department of Biochemistry, University of Wisconsin/United States of America, 2University of Wisconsin/United States of America

Bile Acids (Ba) In Human Pancreatic Necrosis(Pn) Worsen Acute Pancreatitis (Ap) Via a Non-Micellar Interaction With Fatty Acids(Fa)
K. Patel1, B. Khatua1, J.R. Yaron1, C. De Oliveira1, R.J. Singh2, G. Papachristou3, D. Yadav1, K. Lee4, F. Murad5, V.P. Singh1
1Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America, 2Lab Medicine and Pathology, Mayo Clinic, MN/United States of America, 3Medicine, University of Pittsburgh, PA/United States of America, 4Surgery, University of Pittsburgh, PA/United States of America, 5NorthShore University Health System, IL/United States of America
Sp1 Downregulation Leads to Disruption of Endoplasmic Reticulum Homeostasis and Cell Death
Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, USA

Carboxyl Ester Lipase Hybrid Gene and the Unfolded Protein Response: A Novel Trypsin Independent Model of Injury in Pancreatic Acinar Cells
W.M. Sunseri1, G. Jones2, X. Xiao4, M.E. Lowe4
1Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA/USA, 2Children's Hospital of Pittsburgh of UPMC/US, 3UPMC, Children's Hospital of Pittsburgh, Pittsburgh, PA/USA, 4Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/USA

Mptp-Independent Modulation of Bioenergetics by Oxidants Determines Pancreatic Acinar Cell Death Pathway Activation
J. Armstrong1, N. Cash2, J. Morton2, Y. Ouyang1, A. Tepikin2, R. Sutton1, D. Criddle2
1NIHR Pancreases Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, 2Cellular and Molecular Physiology, University of Liverpool/UK

Yap Is Critical Mediator of Tgf-B1 Induced Emt and Cell Invasion in Pancreatic Cancer
X. Li1, Z. Jiang2, Q. Ma2
1Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an/China, 2Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an/China

Selective Regulation of Intraductal Papillary Mucinous Neoplasms by the Bet Family of Chromatin Adaptors
Y. Huang1, C.E. Adams1, K.N. Von Alt1, Y. Kato2, Y. Mizukami1–2, K.C. Patra2, N. Bardeesy2, K.D. Lillemoe1, C. Fernandez-Del Castillo1, A.L. Warshaw1, A.S. Liss1
1Department of Surgery and the Andrew L Warshaw, MD, Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA/USA, 2Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA/USA, 3Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo/Japan

7:00pm

Women in Pancreas Reception & Dinner
Reception Location | Arlington Berkeley Clarendon
Dinner Location | Georgian
Co-chairs | Aida Habtezion, MD, MSc, Kimberly Kelly, PhD, Diane Simeone, MD

Dimensions of Influence and Negotiation
Keynote Speakers | Stephen Blattner, MD MBA
Judith Simmons, MD
exăgoMD
Leadership Strategy, Leadership Structure, Leadership Effectiveness
www.exagomd.com

Jacqueline Rosenthal
Senior Vice President
ZurickDavis
Strategic Solutions in Healthcare Search
www.zurickdavis.com
SATURDAY, October 29
Grand Ballroom A

7:00 – 8:30am  Breakfast
Location | Georgian ABC

8:30 – 10:00am  Pancreatic Cancer Abstract Session
Location | Grand Ballroom A
Moderators | Sulagna Banerjee, PhD and Marina Pasca Di Magliano, PhD

Haploinsufficiency of Beclin1 Inhibits Panin Development in a Krasg12d Mouse Model of Pancreatic Tumorigenesis
K. Takakura1, E. Mascarinas2, B. Decant3, D. Dawson3, G. Eibl4, A. Gukovskaya5, P. Grippo6
1Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA/United States of America, 2Medicine, University of Illinois-Chicago, IL/United States of America, 3Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, CA/United States of America, 4Surgery, David Geffen School of Medicine at UCLA, CA/United States of America, 5Medicine, David Geffen School of Medicine at UCLA, CA/United States of America

A Novel β2 Adrenergic-Nerve Growth Factor Feed Forward Loop Promotes Pancreatic Cancer
B.W. Renz1, R. Takahashi2, M. Macchini1, T. Tanaka1, Y. Hayakawa3, C.B. Westphalen1, M. Ilmer1, X. Chen2, A. Kleespies1, D.L. Worthley5, A.C. Iuga6, J. Werner1, K.P. Olive6, T.C. Wang2
1Department of General, Visceral, Vascular and Transplantation Surgery, University of Munich, Munich/Germany, 2Division of Digestive and Liver Diseases, Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America, 3University of Tokyo/Japan, 4University of Munich/Germany, 5University of Adelaide/Australia, 6Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America

Serum Exosomal Microrna-191, -21, -451a Are Considered To Be Efficient Diagnostic Marker of Pancreatic Neoplasm
Asahikawa medical university/Japan

Egfr1 Targeted Delivery of 5 Fluorouracil Using Tumor Specific Theranostic Aptamers in Pancreatic Ductal Adenocarcinoma
U.M. Mahajan1, J.P. Kühn2, T. Marschall1, B. Appel1, F. Lämmerhirt1, M. Sendler1, P.R. Wagh1, S. Müller1, F.-U. Weiss1, M.M. Lerch1, J. Mayerle1
1Department of Medicine A, University Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald/Germany, 2Department of Diagnostic Radiology and Neuroradiology, University Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany/Germany, 3Institute of Biochemistry, Ernst-Moritz-Arndt University, Greifswald, Germany/Germany

Regulation of Yes-Associated Protein 1 in Activated Pancreatic Stellate Cells
Cedars-Sinai Medical Center/United States of America
Risk of Malignant Transformation in Suspected Branch Duct Intraductal Papillary Mucinous Neoplasms Extends Beyond 5 Years
I. Pergolini1, K. Sahora1, C.R. Ferrone1, W.R. Brugge2, M. Patino3, K.D. Lillemoe1, A.L. Warshaw1, C. Fernandez-Del Castillo1
1Department of Surgery, Massachusetts General Hospital, Boston, MA/United States of America, 2Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, 3Department of Radiology, Massachusetts General Hospital, MA/United States of America

Surgical Resection Following Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer: Re-Defining the Standards
M. Sandini1, G. Marchegiani1, L. Maggino1, E. Viviani1, A. Montresor1, A. Binco1, G. Malleo2, R. Salvia1, C. Bassi1
1Department of Surgery, Pancreas Institute, University of Verona Hospital/Italy, 2Surgery B, AOUI Verona Hospital Trust/Italy

10:00 – 10:30am
MINI SYMPOSIUM: Update on NIH Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
Location | Grand Ballroom A
Moderators | Jose Serrano, MD, PhD and Jo Ann S. Rinaudo, PhD

Chris E. Forsmark, MD, University of Florida
Stephen J. Pandol, MD, Cedars-Sinai Medical Center
The Goals and Structure of the CPDPC Consortium

Ziding Feng, PhD, MD Anderson
CPDPC Coordinating Center

Suresh T. Chari, MD, Mayo Clinic College of Medicine and Anirban Maitra, MBBS, MD Anderson
Early Detection of Pancreatic Cancer

Mark Goodarzi/ Aida Habtezion, MD, MSc, Stanford Medicine
Type 3 C diabetes and interactions between exocrine and endocrine disorders of the pancreas

Recurrent and Chronic Pancreatitis: Natural history, prevention and treatment
ADULTS:
Darwin Conwell, MD, Ohio State University, Wexner Medical Center
Dhiraj Yadav, MD, MPH, University of Pittsburgh
PEDIATRIC:
Aliye Uc, MD, University of Iowa Carver College of Medicine
Mark E. Lowe, MD, PhD, Children’s Hospital of Pittsburgh of UPMC

10:30 – 10:45am
Break
Location | Grand Ballroom B Pre-function

10:45 – 12:00pm
MINI SYMPOSIUM: Regeneration, inflammation and cancer
Location | Grand Ballroom A
Moderators | Miklos Sahin-Toth, MD, PhD and Kimberly Kelly, PhD
Peter Storz, PhD, Mayo Clinic, Jacksonville
Acinar-to-ductal metaplasia (ADM) in pancreatic disease

Ravikanth Maddipati, MD, University of Pennsylvania, Perelman School of Medicine
Clonality in ADM and PanIN: Lessons to pancreatic cancer

Fernando D. Camargo, PhD, Stem Cell Program, Boston Children's Hospital
Liver regeneration. Lessons that might apply to the pancreas

Qiao Zhou, PhD, Harvard Stem Cell Institute
Derivation of insulin-secreting beta cells from stomach tissues

12:00 – 1:15pm MINI SYMPOSIUM: PanCan Young Investigators
Location | Grand Ballroom A
Moderators | Nipun Merchant, MD and Diane Simeone, MD

Nada Kalaany, PhD, Harvard Medical School / Boston Children’s Hospital
Role of Arginine Metabolism in Obesity-associated Pancreatic Cancer

Ethan Abel, PhD, University of Michigan
HNF1A Regulates Pancreatic Cancer Stem Cell Function

Gregory L. Beatty, MD, PhD, University of Pennsylvania
Immunotherapy for pancreatic cancer – the challenges and opportunities

Kirsten L. Bryant, PhD, University of North Carolina at Chapel Hill
Dual Inhibition of KRAS-Effector Signaling and Autophagy Synergistically Impairs Pancreatic Cancer Cell Proliferation

1:15pm Lunch
Location | Georgian
P1-1
TRAINING FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) IN CHILDREN: INSIGHTS FROM THE KIDS. S. El-Dika1, K. Williams2, A. Hinton1, S. McCarthy1, J.R. Groce1, P. Hart1, S.G. Krishna1, D. Conwell1; 1Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, 2Nationwide Childrens Hospital, Columbus, OH/United States of America

P1-2
TFF1 (TREFOIL FACTOR FAMILY 1) ACT AS TUMOR SUPPRESSOR TO INHIBIT INVASIVE TRANSFORMATION OF PANIN INTO PDAC IN VIVO. J. Yamaguchi, Y. Yokoyama, T. Kokuryo, M. Nagino; Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/Japan

P1-3
LIPOCALIN-2 PROMOTES OBESITY-INDUCED PANCREATIC DUCTAL ADENOCARCINOMA BY REGULATING INFLAMMATION IN THE TUMOR MICROENVIRONMENT. S.B. Gomez1, A.K. Swidnicka-Siergiejko1, N. Badi2, M. Chavez-Tomar2, G. Lesinski2, T. Bekaii-Saab3, M.R. Farren2, T. Mace2, C. Schmidt4, Y. Liu1, D. Deng1, R. Hwang5, L. Zhou5, T. Moore5, D. Chatterjee6, H. Wang6, X. Leng7, R. Arlinghaus7, C.D. Logsdon1, Z. Cruz-Monserrate2; 1Cancer Biology, University of Texas, M. D. Anderson Cancer Center/United States of America, 2Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus/United States of America, 3Hematology and Medical Oncology, Mayo Clinic, AZ/United States of America, 4Surgery, The Ohio State University Wexner Medical Center, OH/United States of America, 5Surgery, University of Texas, M. D. Anderson Cancer Center, TX/United States of America, 6Pathology, University of Texas, M. D. Anderson Cancer Center/United States of America, 7Translational Molecular Pathology, University of Texas, M. D. Anderson Cancer Center/United States of America

P1-4
GENETIC ABLATION OF MITOCHONDRIAL DEACETYLASE SIRTUIN 3 EXACERBATES CERULEIN PANCREATITIS. Y. Qin1, 2, J. Yuan1, S.R. Mallal1, M. Geng1, 3, R.T. Waldron1, 4, O.A. Mareninova1, A. Lugea1, 4, S.J. Pandol1, 4, A.S. Gukovskaya1; 1VA Greater Los Angeles Healthcare System, University of California at Los Angeles, and Southern California Research Center for ALPD and Cirrhosis, Los Angeles, California, CA/United States of America, 2The Division of Gastroenterology and Hepatology, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region/China, 3Frank Netter H. MD School of Medicine at Quinnipiac University, CT/United States of America, 4Cedars-Sinai Medical Center, Los Angeles/United States of America

P1-5
ENDO180 REGULATE PHOSPHORYLATION OF MYOSIN LIGHT CHAIN 2 ACTIVITY AND INCREASE THE ABILITY OF EXTRACELLULAR MATRIX REMODELING IN LEADING PANCREATIC STELLATE CELLS. K. Koikawa, K. Ohuchida, S. Kibe, Y. Ando, S. Takesue, H. Nakayama, T. Abe, S. Endo, T. Okumura, T. Moriyama, K. Nakata, Y. Miyasaka, T. Manabe, T. Ohtsuka, E. Nagai, K. Mizumoto, M. Nakamura; Department of Surgery and Oncology, Kyushu University/Japan

P1-6
DIABETES BURDEN FOLLOWING TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION (TPIAT). A. Lane1, P. Ptacek1, K.L. Berry2, T.B. Dunn2, T.L. Preutt2, M. Cook2, S. Chinnakotla2, M. Freeman2, S.J. Schwarzenberg1, G.J. Beilman2, M. Bellin1, 2, 3; 1Pediatrics, University of Minnesota, Minneapolis, MN/United States of America, 2Surgery, University of Minnesota, Minneapolis, MN/United States of America, 3Medicine, University of Minnesota, Minneapolis, MN/United States of America

P1-7
LOSS OF NECROPTOTIC RIP3 CAN NOT ATTENUATE IMPAIRED AUTOPHAGY-INDUCED PANCREATITIS. X. Zhou1, L. Xie2, F. Bergmann3, O. Strobel4, M.W. Büchler4, T. Hackert4, F. Fortunato2; 1Section surgical research, University Clinic Heidelberg, Heidelberg/Germany, 2Section of surgical research, University Clinic Heidelberg, Heidelberg/Germany, 3Institute of Pathology, University Clinic Heidelberg/Germany, 4Department of General Surgery, University Hospital Heidelberg/Germany

47TH ANNUAL MEETING          OCTOBER 26-29, 2016  BOSTON, MA  28
P1-8
CLINICAL IMPACT OF NONSELECTIVE BETA-BLOCKERS ON SURVIVAL IN PATIENTS WITH PANCREATIC CANCER- REVIVAL OF WELL KNOWN DRUGS? B.W. Renz1, S. Grafl, B. Mayer1, M. Macchini2, S. Vecchiarelli3, C. Ricci3, T.C. Wang2, R. Casadei3, M. Di Marco3, A. Kleespies1, J. Werner1; 1Department of General, Visceral, Vascular and Transplantation Surgery, University of Munich, Munich/Germany, 2Division of Digestive and Liver Diseases, Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America, 3University of Bologna/Italy

P1-9
GENETIC DELETION OF THE ADAPTOR PROTEIN, AP3, RESULTS IN SECRETORY AND PROCESSING DEFECTS IN ACINAR CELLS. A.J. Cepleski1, C.A. Shugrue1, T. Kolodecik1, G. Groblewski2, S. Messenger2, D.D. Thomas2, F. Gorelick1, 3; 1Internal Medicine digestive diseases, Yale University/United States of America, 2University of Wisconsin/United States of America, 3Veterans Administration CT Healthcare/United States of America

P1-10
RENALASE FORMS HIGH MOLECULAR WEIGHT COMPLEX IN PLASMA FOR TISSUE TRANSLOCATION IN ACUTE PANCREATITIS. K. Date1, 2, T. Kolodecik1, F. Gorelick1, 3; 1Internal Medicine digestive diseases, Yale University/United States of America, 2Graduate School of Humanities and Science, Ochanomizu University/Japan, 3Veterans Administration CT Healthcare/United States of America

P1-11
ORAL ADMINISTRATION IS AS EFFECTIVE AS INTRAPERITONEAL ADMINISTRATION OF MINNELIDE AGAINST PANCREATIC CANCER. N. Sharma, S. Modi, B. Giri, J. George, B. Garg, V. Sethi, S. Banerjee, V. Dudeja, A. Saluja; Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, FL

P1-12
HSP70 DEFICIENT IMMUNE CELLS LEAD TO GREATER IMMUNE MEDIATED KILLING IN PANCREATIC CANCER. B. Giri1, B. Garg2, S. Modi2, V. Sethi1, J. George3, S. Ramakrishnan2, S. Banerjee1, A.K. Saluja4, V. Dudeja2; 1University of Miami, University of Miami, Miami/United States of America, 2University of Miami/United States of America, 3Surgery, University of Miami/United States of America, 4Surgery, University of Miami, FL/United States of America

P1-13
PARANEOPLASTIC WEIGHT LOSS IN PANCREATIC CANCER (PC) WITH SELECTIVE REDUCTION IN SUBCUTANEOUS RELATIVE TO VISCERAL FAT MEDIATED BY PC EXOSOMES. R.P. Sah1, S. Nagpall1, A. Sharma1, N. Ahmed1, S. Mohapatra1, N. Takahashi1, D. Mukhopadhyay2, S.T. Chari1; 1Mayo Clinic, MN/United States of America, 2Mayo Clinic, FL/United States of America

P1-14

P1-15
EXTRACELLULAR CA2+ CONTRIBUTES TO THE BENEFICIAL EFFECTS OF LACTATED RINGER'S DURING ACUTE PANCREATITIS. J.R. Yaron, K. Patel, B. Khauta, C. De Oliveira, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

P1-16
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS IN YOUNG PATIENTS EXHIBIT DISTINCT BIOLOGY, CLINICOPATHOLOGICAL CHARACTERISTICS, AND FAVORABLE PROGNOSIS. V. Morales-Oyarvide1, M. Mino-Kenudson2, C.R. Ferrone1, A.L. Warshaw1, K.D. Lillemoe1, I. Pergolini1, M. Attiyeh3, N. Rezaee4, P.J. Allen3, C.L. Wolfgang3, C. Fernandez-Del Castillo1; 1Department of Surgery, Massachusetts General Hospital, Boston/United States of America, 2Department of Pathology, Massachusetts
General Hospital, Boston/United States of America, 3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City/United States of America, 4Department of Surgery, Johns Hopkins University School of Medicine, Baltimore/United States of America

P1-17
DOES FAMILY HISTORY PREDICT GENETIC TEST RESULTS FOR CHRONIC PANCREATITIS? R.E. Brand1, N. Shah2, D. Yadav1, A. Slivka1, J. Larusch1, D. Whitcomb1; 1Department of Medicine, University of Pittsburgh Medical Center, PA/United States of America, 2Dental Public Health, University of Pittsburgh Medical Center/United States of America

P1-18
NALTREXONE REDuces AND MORPHINE WORSENS CHRONIC PANCREATITIS PROGRESSION IN MOUSE MODELS OF THE DISEASE. J. George1, H. Cheema1, A. Dixit2, U. Barlass1, B. Giri3, Y. Ryu2, S. Banerjee1, S. Roy1, R. Dawra2, A.K. Saluja2, V. Dudeja5; 1Surgery, University of Miami/United States of America, 2Surgery, University of Miami, FL/United States of America, 3University of Miami, University of Miami, Miami/United States of America, 4Surgery, University of Minnesota/United States of America, 5University of Miami/United States of America

P1-19
LAPAROSCOPIC-ASSISTED VERSUS OPEN TOTAL PANCREATECTOMY AND ISLET AUTOTRANSPLANTATION: A CASE-MATCHED STUDY OF PEDIATRIC PATIENTS. M. Berger1, T.B. Dunn1, G.J. Beilman1, M. Freeman2, M. Bellin3, S.J. Schwarzenberg3, S. Chinnakotla1; 1Surgery, University of Minnesota, Minneapolis, MN/United States of America, 2Medicine, University of Minnesota, Minneapolis, MN/United States of America, 3Pediatrics, University of Minnesota, Minneapolis, MN/United States of America

P1-20
PANCREATIC DUCTAL ADENOCARCINOMA CAN BE GENERATED FROM HUMAN ACINAR CELLS. N. Akanuma1, J. Liu1, F.E. Sharkey2, A.D. Singhi3, H. Crawford4, P. Wang1; 1Department of Cellular and Structural Biology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, 2Department of Pathology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, 3Department of Pathology, University of Pittsburgh Medical Center/United States of America, 4Department of Molecular and Integrative Physiology & Internal Medicine, University of Michigan/United States of America

P1-21
ADIPORON SUPPRESSES CYTOKINE MEDIATED STAT3 ACTIVATION THROUGH SOCS3 TO INHIBIT PANCREATIC CANCER GROWTH. F. Messaggio, N. Nagathihalli, N. Merchant, M. Vansaun; Department of Surgery, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL/United States of America

POSTERS

P1-22
PANCREAS DIVISUM IS ASSOCIATED WITH A HIGHER RISK OF RECURRENT ACUTE PANCREATITIS ONLY IN THE PRESENCE OF PRSS1 AND CATHEPSIN B POLYMORPHISMS. M. Aslam1, S. Avanthi2, V.V. Ravikanth2, B. Govardhan2, N. Zaheer2, D.N. Reddy2, R. Telukdar2; 1Medical Gastroenterology, Asian Institute of Gastroenterology/India, 2Asian Institute of Gastroenterology/India

P1-23
FUNCTIONAL STUDIES IMPLICATE AN IMBALANCED ACTIVATION OF DENDRITIC CELLS IN THE PATHOGENESIS OF MURINE AUTOIMMUNE PANCREATITIS. L. Borufka1, E. Volmer1, S. Müller1, R. Engelmann2, H. Nisse3, S. Ibrahim1, R. Jaster1; 1Department of Medicine, Division of Gastroenterology, Rostock University Medical Center, Rostock/Germany, 2Institute of Immunology and Core Facility for Cell Sorting & Cell Analysis, Rostock University Medical Center/Germany, 3Institute of Pathology, Rostock University Medical Center/Germany, 4Institute of Experimental Dermatology, University of Luebeck/Germany
P1-24
INCIDENCE AND TIMING OF THE DEVELOPMENT OF CONCOMITANT PANCREATIC DUCTAL ADENOCARCINOMA DURING SURVEILLANCE FOR RESECTED AND UNRESECTED INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. K. Date1, T. Ohtsuka1, S. Nakamura1, Y. Gotoh1, Y. Nakashima1, T. Fujimoto1, K. SaeKI2, N. Mochidome2, Y. Mori1, Y. Sadakari1, K. Nakata1, Y. Miyasaka1, K. Ohuchida1, T. Manabe1, E. Nagai1, Y. Oda2, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, 2Department of Anatomic Pathology, Kyushu University, Fukuoka/Japan

P1-25
DOWNSIZING CHEMOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE FOLLOWED BY RADICAL SURGERY: TOXICITY AND CLINICAL OUTCOME. S. Kagawa, H. Yoshitomi, H. Shimizu, M. Ohtsuka, K. Furukawa, T. Takayashiki, S. Takano, S. Kuboki, D. Suzuki, N. Sakai, H. Nojima, M. Miyazaki; Department of General Surgery, Chiba University, Chiba/Japan

P1-26
THE RELATIONSHIP OF NUTRITIONAL STATUS WITH PAIN MEDICATION USE IN CHRONIC PANCREATITIS PATIENTS. L. Bocelli1, M. Min2, B. Patel3, S. Han4, J. Kheder1, W. Wassef1; 1Gastroenterology, University of Massachusetts Medical Center/United States of America, 2Internal Medicine, University of Massachusetts Medical Center, MA/United States of America, 3Internal Medicine Residency, UMass Medical School/United States of America, 4Gastroenterology, University of Colorado School of Medicine, CO/United States of America

P1-27
RISK FACTORS FOR ASPARAGINASE ASSOCIATED PANCREATITIS: A SYSTEMATIC REVIEW. F.T. Rose1, J.-A. Oparaji2, A. Orahi3, A.S. Howard3, D.C. Okafor3, R. Turner4, M.E. Lowe1, K.A. Ritchey1, S.Z. Husain1; 1Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America, 2Pediatrics, Walter Reed National Military Medical Center, MD/United States of America, 3School of Medicine, University of Pittsburgh, PA/United States of America, 4University of Pittsburgh, PA/United States of America

P1-28
MALNUTRITION AND PANCREATIC ENZYME SUPPLEMENTATION IN CHRONIC PANCREATITIS PATIENTS. M. Min1, B. Patel2, S. Han3, J. Kheder4, L. Bocelli4, W. Wassef4; 1Internal Medicine, University of Massachusetts Medical Center, MA/United States of America, 2Internal Medicine Residency, UMass Medical School/United States of America, 3Gastroenterology, University of Colorado School of Medicine, CO/United States of America, 4Gastroenterology, University of Massachusetts Medical Center/United States of America

P1-29
CONTRIBUTION OF ACTIVATING TRANSCRIPTION FACTOR 3 TO DEVELOPMENT OF ACINAR-TO-DUCTAL CELL METAPLASIA. J. Toma1, C. Young1, K. Berger1, C. Pin1, 2; 1Physiology and Pharmacology, University of Western Ontario, Children's Health Research Institute, University of Western Ontario/Canada, 2Paediatrics, University of Western Ontario, London/Canada

P1-30
A CASE PRESENTATION OF DISTAL BILE DUCT ADENOCARCINOMA; DISTINGUISHING BETWEEN CHOLANGIOCARCINOMA AND PANCREATIC DUCTAL ADENOCARCINOMA. H. Karasaki, Y. Mizukami, Y. Ono, M. Ogata, D. Yoshikawa, T. Macekina, K. Nagashima, T. Kono; Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan

P1-31
IKK-EPSILON ENHANCES NUCLEAR-RETENTION AND STABILIZATION OF C-MYC TO PROMOTE GLYCOLYTIC-METABOLISM AND PANCREATIC TUMOR GROWTH. H. Zubair1, S. Azim1, S.K. Srivastava1, A. Ahmad1, A. Bhardwaj1, M.A. Khan1, G.K. Patel1, S. Arora1, J.E. Carter2, S. Singh1, A.P. Singh1, 3; 1USA Mitchell Cancer Institute, Mobile, AL/United States of America, 2Department of Pathology, College of Medicine University of South Alabama, Mobile, AL/United States of America, 3Department of Biochemistry and Molecular Biology, College of Medicine University of South Alabama, Mobile, AL/United States of America
P1-32
DELETION OF ATRX IN ADULT Pancreatic Acinar Cells Leads to Increased Cell Stress, DNA Damage, and Sensitivity to Pancreatitis. R. Baker1, C. Young2, C. Howlett3, C. Pin4; 1Biology, Children's Health Research Institute, University of Western Ontario, London/Canada, 2Physiology & Pharmacology, University of Western Ontario, Children's Health Research Institute, London/Canada, 3Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada, 4Paediatrics, University of Western Ontario, London/Canada

P1-33
Next Generation Sequencing to Detect Deleterious Germline Mutations in Patients with Apparently Sporadic Pancreatic Ductal Adenocarcinoma. K. Shindo1, J. Yu1, M. Suefagot1, S. Fesharizadeh1, J.A.N. Almanio1, A. Siddiqui1, M. Borges1, C. Cho1, N. Roberts1, R. Hruban1, A. Klein2, M. Hashizume3, M. Nakamura4, M. Goggins1; 1Pathology department, The Johns Hopkins University, MD/United States of America, 2Oncology, The Johns Hopkins University School of Medicine/United States of America, 3Center for Advanced Medical Innovation, Kyushu University/Japan, 4Department of Surgery and Oncology, Kyushu University/Japan

P1-34
Functional Role of 4F2HC in Pancreatic Ductal Adenocarcinoma. D. Bianconi1, M. Herac2, A. Gleiss3, M. Unseld4, R. Weigl5, M. Schindl5, W. Scheithauer6, C. Zielinski6, G. Prager4; 1Internal Medicine I, Oncology, Medical University of Vienna, Vienna/Austria, 2Clinical Institute of Pathology, Medical University of Vienna/Austria, 3Section for Clinical Biometrics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna/Austria, 4Internal Medicine I, Oncology, Medical University of Vienna/Austria, 5Department of Surgery, Medical University of Vienna/Austria

P1-35
Inverted U Dose-Response of Nonspecific Cyclophilin Inhibitor Cyclosporin A On Murine Pancreatic Acinar Cell Injury and Experimental Acute Pancreatitis. X.Y. Zhang1, M. Chvanov2, D. Latawiec1, L. Wen1, Y. Ouyang2, R. Mukherjee1, W. Huang1, 3, A. Tepikin2, D. Criddle2, R. Sutton1; 1NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom, 2Department of Cellular and Molecular Physiology, University of Liverpool/United Kingdom, 3Department of Surgery, Liverpool/United Kingdom, 4Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University/China

P1-36

P1-37
Pathophysiologic modulation of Pancreatic Acinar Cell Bioenergetics by Cholecystokinin. J. Morton1, 2, J. Armstrong2, N. Cash1, Y. Ouyang1, A. Tepikin1, R. Sutton2, D. Criddle1, 2; 1Dept. of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool/United Kingdom, 2NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital University of Liverpool/United Kingdom

P1-38
Collaboration between Autophagy, the Unfolded Protein Response, and Endosomal Trafficking Maintains Acinar Cell Differentiation. E. Jones1, S. Messenger1, M. Cooley1, D.D. Thomas1, R.T. Waldron2, 3, A. Lugea2, 3, S.J. Pandol2, 3, G. Groblewski1; 1University of Wisconsin/United States of America, 2Cedars-Sinai Medical Center, Los Angeles/United States of America, 3VA Greater Los Angeles Healthcare System, University of California at Los Angeles, CA/United States of America
P1-39
POLYMORPHISM OF THE HEME OXYGENASE-1 (HO-1) PROMOTER AND CYTOKINES EXPRESSION IN ACUTE PANCREATITIS. A.K. Gulla1, A. Gulbinas2, G. Barauskas2, Z. Dambruoskas2; 1Department of Surgery, Georgetown University Hospital, Washington DC/United States of America, 2Department of Surgery, Lithuanian University of Health Sciences, Kaunas/Lithuania

P1-40
NF-KB ACTIVATION WITH RADIOCONTRAST EXPOSURE DURING POST-ERCP PANCREATITIS IS DEPENDENT ON BCL10 IN THE SCAFFOLDING CBM COMPLEX. S. Sanker, A.I. Orabi, D. Hu, L.M. McAllister-Lucas, P.C. Lucas, S.Z. Husain; Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC. University of Pittsburgh, Pittsburgh, PA/United States of America

P1-41

P1-42
KNOCKING DOWN ZIP4 INHIBITS EPITHELIAL-MESENCHYMAL TRANSITION-INDUCED METASTASIS OF Pancreatic Cancer Cells. M. Liu1, J. Yang1, C. Houchen1, R. Postier2, M. Li1, 2; 1Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK/United States of America, 2Surgery, University of Oklahoma Health Science Center/United States of America

P1-43
COMPARISON OF THE INTERNATIONAL CONSENSUS GUIDELINES FOR PREDICTING MALIGNANCY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. S. Yamada, T. Fujii, H. Takami, M. Hayashi, H. Sugimoto, Y. Kodera; Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, Nagoya/Japan

P1-44
FUNCTIONAL AND NON-FUNCTIONAL Pancreatic Neuroendocrine Tumours. M. Yang; Department of Pancreatic Surgery, West China Hospital, Sichuan University/China

P1-45
RISK FACTOR OF POSTOPERATIVE Pancreatic Fistula After Distal Pancreatectomy Using Triple-Row stapler. H. Kawaida, M. Watanabe, N. Hosomura, H. Amemiya, H. Kono, M. Matsuda, H. Fujii; First Department of Surgery, University of Yamanashi, Chyuo-shi, Yamanashi/Japan

P1-46
RISK FACTORS FOR Pancreatic Stone Formation in Type 1 Autoimmune Pancreatitis: A Nationwide Survey by the Japan Pancreas Society. T. Ito1, S. Kawa2, K. Kubota3, T. Kamisawa4, K. Okazaki5, T. Shimosogawa6; 1Gastroenterology, Shinshu University School of Medicine, Matsumoto/Japan, 2Center for Health, Safety, and Environmental Management, Shinshu University, Matsumoto/Japan, 3Gastroenterology, Yokohama City University Graduate School of Medicine/Japan, 4Gastroenterology, Tokyo Metropolitan Komagome Hospital/Japan, 5Gastroenterology, Kansai Medical University/Japan, 6Gastroenterology, Tohoku University Graduate School of Medicine/Japan

P1-47
A QUALITY OF LIFE COMPARISON IN CHRONIC Pancreatitis Patients Between Smokers and Non-Smokers. B. Patel1, M. Min1, S. Han2, J. Kheder3, L. Bocelli3, A. Wachholtz4, W. Wassef3; 1Internal Medicine, University of Massachusetts Medical School/United States of America, 2Division of Gastroenterology and Hepatology, University of Colorado, CO/United States of America, 3Department of Gastroenterology, University of Massachusetts Medical Center/United States of America, 4Psychiatry, University of Massachusetts, MA/United States of America
P1-48

P1-49
OPTIMIZATION OF ONCOLYTIC CHEMOVIRAL PROTOCOLS FOR THERAPY OF PANCREATIC CANCER. S.P. Grekova1, A. Heller1, A.L. Angelova2, M. Aprahamian3, T. Giese4, E. Soyka1, S. Bauer1, S. Rüffer4, J. Rommelaere2, T. Hackert1, O. Strobel1, Z. Raykov2, N. Giese1; 1Department of General Surgery, University Hospital Heidelberg/Germany, 2Programme Infection and Cancer, Tumor Virology Division F010, DKFZ/Germany, 3Institut de Recherche Contre les Cancers de l'Appareil Digestif (IRCAD)/France, 4Institute of Immunology, University Hospital Heidelberg/Germany

P1-50
CORRELATION OF A LONG NON-CODING RNA, H19, WITH METASTASIS OF PANCREATIC CANCER. T. Ishiwata1, H. Yoshimura2, Y. Matsuda3, N. Ishikawa1, K. Takubo1, T. Arai3, J. Aida1; 1Department of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo/Japan, 2Division of Physiological Pathology, Department of Applied Science, School of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, Tokyo/Japan, 3Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan

P1-51
INTERLEUKIN (IL) 10 AND PYRIDONE 6 (P6) MODIFY THE MIGRATION OF PANCREATIC CANCER CELLS IN CO-CULTURES WITH MACROPHAGES. A. Salmiheimo1, 2, H. Mustonen1, 2, S. Vainionpää1, 2, E. Kemppainen1, 2, P. Puolakkainen1, 2, H. Seppänen1, 2; 1Helsinki University Hospital/Finland, 2University of Helsinki/Finnland

P1-52
TFF1 MIGHT INHIBIT INVASION BUT ACCELERATE LYMPH NODE METASTASIS OF PANCREATIC DUCTAL ADENOCARCINOMA. M. Sunagawa, J. Yamaguchi, Y. Yokoyama, T. Kokuryo, M. Nagino; Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/Japan

P1-53
CIRCUIMENTAL PANCREAS, A RARE CONGENITAL ANOMALY, INCREASES A RISK OF PANCREATIC FISTULA AFTER PANCREATECTOMY. T. Ohtsuka1, Y. Mori1, K. Ishigami2, T. Fujimoto1, Y. Miyasaka1, K. Nakata1, K. Ohuchida1, T. Manabe1, E. Naga1, Y. Oda3, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University/Japan, 2Department of Clinical Radiology, Kyushu University/Japan, 3Department of Anatomical Pathology, Kyushu University/Japan

P1-54
PARTICIPATION OF CRK-ASSOCIATED SUBSTRATE (CAS) IN HUMAN PANCREATIC CANCER CELL MIGRATION, INVASION AND METASTATIC PROCESSES. G.-Y. Liou1, B. Edenfield1, L. Zhang2, D. Dawson3, N. Bardeesy4, P. Storz1; 1Cancer Biology, Mayo Clinic, FL/United States of America, 2Laboratory Medicine & Pathology, Mayo Clinic/United States of America, 3Pathology & Laboratory Medicine, UCLA/United States of America, 4Department of Medicine, Harvard Medical School/United States of America
P1-56
INVASIVE SIZE PREDICTS RECURRENCE AND SURVIVAL OF SMALL INVASIVE CARCINOMA ARISING IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS. M. Mino-Kenudson1, V. Morales-Oyarvide2, K. Date3, T. Ohtsuka3, Y. Omori4, M. Tanino5, Y. Mizukami6, S.-M. Hong7, D.W. Hwang8, S.C. Kim8, G. Zamboni9, P. Castelli10, R. Higuchi11, M. Yamamoto11, K. Shimizu12, M. Nakamura13, H. Maguchi13, C. Fernandez-Del Castillo14, T. Furukawa15; 1Department of Pathology, Massachusetts General Hospital, MA/United States of America, 2Dana Faber Cancer Center, MA/United States of America, 3Department of Surgery and Oncology, Kyushu University, Japan, 4Department of Pathology, Teine Keijinkai Hospital, Sapporo, Japan, 5Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Japan, 6Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Japan, 7Pathology, Asan Medical Center, University of Ulsan College of Medicine, Korea, Republic of, 8Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea, Republic of, 9Pathology, University of Verona and Don Calabria Hospital, Italy, 10Pathology, Don Calabria Hospital, Italy, 11Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Japan, 12Gastroenterology, Institute of Gastroenterology, Tokyo Women's Medical University, Japan, 13Center for Gastroenterology, Teine Keijinkai Hospital, Japan, 14Department of Surgery, Massachusetts General Hospital, MA/United States of America, 15Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Japan

P1-57
CHANGES IN THE EXPRESSION OF RRM SUBUNITS INDUCE GEMCITABINE RESISTANCE IN A GROWTH DEPENDENT MANNER. K.S. Mann, S. Brumskill, P. Ghaneh, W. Greenhalf; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Bx/United Kingdom

P1-58
INHIBITION OF JAK/STAT SIGNALING LIMITS THE ACTIVATION OF PANCREATIC STELLATE CELLS IN VITRO AND CAERULEIN-INDUCED PANCREATITIS IN VIVO. H. Komar1, T. Mace1, G. Serpa1, O. Elhagger1, D. Conwell2, P. Hart2, C. Schmidt3, M. Dillhoff1, J. Ming1, G. Lesinski1; 1The Ohio State University/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, 3Department of Internal Medicine, The Ohio State University Wexner Medical Center, OH/United States of America, 4Department of Surgery, The Ohio State University Wexner Medical Center, OH/United States of America, 5Department of Surgery, The Ohio State University Wexner Medical Center, Columbus/United States of America

P1-59
SURVIVAL AND PROGNOSTIC FACTORS OF NEOADJUVANT TREATMENT AND OPERATION FOR BORDERLINE RESECTABLE PANCREATIC CANCER. H.S. Kim1, J.-Y. Jang1, Y. Han1, K.B. Lee2, J.R. Kim1, H. Kim1, W. Kwon1, S.-W. Kim1; 1Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Republic of, 2Department of Pathology, Seoul National University Hospital/Republic of Korea, Republic of

P1-60
TREATMENT STRATEGY FOR NEUROENDOCRINE TUMOR OF THE PANCREAS. J. Itakura, M. Watanabe, N. Hosomura, H. Amemiya, H. Kawaida, H. Okamoto, H. Kohno; Surgery, University of Yamanashi, Yamanashi, Japan

P1-61
ROLE OF THE HIPPO-YAP AND MSP-RON SIGNALING PATHWAYS IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) METASTASIS TO THE LIVER. Q. Wang, C. Chheda, S. Pandol; Medicine, Cedars-Sinai Medical Center, Los Angeles, CA/United States of America

P1-62
NEOADJUVANT CHEMOTHERAPY FOR PANCREATIC CANCER. E. Hashimoto, H. Shimamura, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai, Japan
P1-63
SERUM LEVEL OF WISTERIA FLORIBUNDA AGGLUTININ-POSITIVE MAC-2-BINDING PROTEIN REFLECTS THE SEVERITY OF CHRONIC PANCREATITIS. T. Fujiyama, K. Ueda, Y. Tachibana, M. Miki, K. Yasunaga, T. Takaoka, K. Kawabe, T. Ito; Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University/Japan

P1-64
VISCERAL ARTERIAL CALCIUM BURDEN AND LIKELIHOOD OF PANCREATIC FISTULA AFTER PANCREATIC RESECTION. A. Gomes1, I. Santiago2, R. Rocha3, R. Marinho3, M. Sousa3, M. Fragoso3, D. Aparício3, A. João3, A. Soares3, V. Nunes3; 1Surgery, Hospital Prof.Dr. Fernando Fonseca/Portugal, 2Champalimaud Foundation/Portugal, 3Surgery, Hospital Prof.Dr. Fernando Fonseca, Amadora/Portugal

P1-65
HISTONE DEMETHYLASE KDM3A REGULATES CANCER STEM CELLS FOR PANCREATIC CANCER PROGRESSION. S. Paul1, C. Ghosh2, D. Subramaniam3, K. Palaniyandi2, T. Iwakuma2, S. Anant3, A. Dhar2; 1Cancer Biology, The University of Kansas Medical Center, Kansas City/United States of America, 2Cancer Biology, The University of Kansas Medical Center, Kansas City, KS/United States of America, 3Surgery, The University of Kansas Medical Center, Kansas City, KS/United States of America

P1-66
ASSOCIATION OF HIGH HLA CLASS I ANTIGEN EXPRESSION WITH POOR PROGNOSIS IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMN). L. Cai1, T. Michelakos1, C. Fernandez-Del Castillo1, M. Mino-Kenudson2, A.L. Warshaw1, K.D. Lillemeoe1, S. Ferrone1, C.R. Ferrone1; 1Department of Surgery, Massachusetts General Hospital, MA/United States of America, 2Pathology, Massachusetts General Hospital, Boston, MA/United States of America

P1-67
IMMUNOLOGICAL EVENTS AND CLINICAL COURSE OF PANCREATIC NEUROENDOCRINE TUMORS (PNETS). T. Michelakos1, L. Cai1, C. Fernandez-Del Castillo1, A.L. Warshaw1, K.D. Lillemeoe1, S. Ferrone1, V. Deshpand2, C.R. Ferrone1; 1Department of Surgery, Massachusetts General Hospital, MA/United States of America, 2Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA/United States of America

P1-68
TARGETING PANCREATIC CANCER BY EGCG IN GEMCITABINE RESISTANCE. C. Ghosh1, S. Paul2, S. Anant3, A. Dhar1; 1Cancer Biology, The University of Kansas Medical Center, Kansas City, KS/United States of America, 2Cancer Biology, The University of Kansas Medical Center, Kansas City/United States of America, 3Surgery, The University of Kansas Medical Center, Kansas City, KS/United States of America

P1-69
BIOGLUE® SEALED FISH-MOUTH CLOSURE OF THE PANCREATIC REMNANT AS A FEASIBLE ALTERNATIVE TO STAPLER CLOSURE DURING LAPAROSCOPICAL DISTAL PANCREATECTOMY. F. Klein, R. Zorron, J. Pratschke, M. Bahra; Department of General, Visceral and Transplantation Surgery, Charite Universitätsmedizin Berlin/Germany

P1-70
A SYSTEMATIC REVIEW AND QUANTITATIVE ANALYSIS OF DIFFERENT THERAPIES FOR PANCREAS DIVISUM. T. Hackert, M. Hafezi, B. Mayschak, P. Probst, M.W. Büchler, A. Mehrabi; Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany

P1-71
NOTCH4 ACTS AS AN ONCOGENIC SIGNAL IN PANCREATIC TUMORIGENESIS. W. Qiu1, S. Chadi1, N. Tsay1, A.R. Chambers1, D.D. Suh1, P.A. Sims2, C.J. Shawber3, J. Kitajewski4, H.E. Remotti5, G.H. Su5; 1Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY/USA, 2Department of Systems Biology, Columbia University, New York, New York, NY/USA, 3Department of Obstetrics and Gynecology, Columbia University, New York, NY/USA, 4Department of Physiology & Biophysics, University of Illinois at Chicago, Chicago, IL/USA, 5Pathology, Columbia University, New York, NY/USA
P1-72 POTENTIAL TARGETS AND ROLE OF EZH2 IN PANCREATIC CANCER. A. Habib, W. Pan, N. Alzofon, S. Wang, S. Urayama; Internal Medicine, University of California, Davis, CA/United States of America

P1-73 EARLY SURGERY IS BENEFICIAL FOR PAIN CONTROL AND PANCREATIC FUNCTION PRESERVATION IN CHRONIC PANCREATITIS: A RETROSPECTIVE STUDY OF 297 CONSECUTIVE PATIENTS. N. Ke1, W. Huang2, Q.M. Nunes2, X. Liu1, R. Sutton2; 1West China Hospital/China, 2Royal Liverpool University Hospital/United Kingdom

P1-74 EVALUATION OF SECRETIN-ENHANCED MRCP IN CHRONIC PANCREATITIS. S. Siminkovitch1, P. Gecov2, B. Vladimirov1, G. Nedelkov2, M. Kovacheva-Slavova1, B. Golemanov1; 1Gastroenterology, University Hospital Tsaritsa Ioanna-ISUL/Bulgaria, 2Medical Imaging, University Hospital Tsaritsa Ioanna-ISUL/Bulgaria

P1-75 HIGH-GRADE PANIN/CARCINOMA IN SITU OF THE PANCREAS ASSOCIATED WITH CYSTIC CHANGES AND FIBROSIS. Y. Matsuda1, T. Furukawa2, S. Yachida3, M. Nishimura4, A. Seki1, K. Nomaka1, J. Aida5, K. Takubo5, T. Ishiwa5, W. Kimmura6, T. Arai7, M. Mino-Kenudson7; 1Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan, 2Institute for Integrated Medical Sciences, Tokyo Women's Medical University/Japan, 3Division of Cancer Genomics, National Cancer Center Research Institute/Japan, 4Department of Endoscopy, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan, 5Department of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology/Japan, 6Department of Gastroenterological, General, Breast & Thyroid Surgery, Yamagata University/Japan, 7Department of Pathology, Massachusetts General Hospital, MA/United States of America

P1-76 DOES UNAVAILABILITY OF BILIARY INTERVENTION AT RURAL AND SMALL HOSPITALS IMPACT IMMEDIATE PATIENT OUTCOMES IN BILIARY ACUTE PANCREATITIS? A NATIONAL ANALYSIS. A. Malli1, S. El-Dika2, S. McCarthy1, J.R. Groce2, A. Hinton2, D. Conwell2, S.G. Krishna2; 1Ohio State University-Wexner Medical Center, OH/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P1-77 STATIN USE IS NOT ASSOCIATED WITH SIRS OR OUTCOMES IN ACUTE PANCREATITIS. J. McNabb-Baltar1, V. Antoine-Gustave2, V. Kadiyala3, D.X. Jin3, S.L. Suleiman3, D. Conwell4, P.A. Banks3; 1Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 2Gotham Medical Associates/United States of America, 3Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 4Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P1-78 ADJUVANT CHEMOTHERAPY AFTER RESECTION OF PANCREATIC DUCTAL ADENOCARCINOMA - A RETROSPECTIVE SINGLE CENTER ANALYSIS OF 251 CONSECUTIVE PATIENTS IN A NON-SELECTED COHORT. U.A. Wittel, M. Reinmuth, F. Makowiec, O. Sick, R.M. Fritsch, U.T. Hopt; University of Freiburg Medical Center/Germany

P1-79 RADIOCONTRAST INDUCES MITOCHONDRIAL DYSFUNCTION AND IMPAIRED MITOPHAGY IN POST-ERCP PANKREATITIS THROUGH THE DEPHOSPHORYLATION OF DRP1 BY CALCINEURIN. L. Wen1, N. Shalbueva2, O.A. Mareninova2, A.I. Orabi1, T.A. Javed1, A.S. Gukovkaya2, S.Z. Husain1; 1Department of Pediatric, University of Pittsburgh and the Children's Hospital of Pittsburgh of UPMC, United States of America, Pittsburgh, PA/United States of America, 2Veterans Affair Greater Los Angeles Healthcare System, University of California Los Angeles and Southern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, CA/United States of America
P1-80
RADICAL CARBON-ION RADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER. K. Nakata1, T. Ohtsuka1, Y. Mori2, Y. Miyasaka1, S. Makoto3, E. Naga1, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University/Japan, 2Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, 3On Beam Therapy Center, SAGA HIMAT Foundation/Japan

P1-81
AN INTERNATIONAL EXTERNAL INTER-AND INTRA OBSERVER VARIABILITY STUDY EVALUATING NEEDLE BASED CONFOCAL LASER ENDOMICROSCOPY (NCLE) FOR DIAGNOSIS OF PANCREATIC CYSTIC LESIONS (PCLS). S.G. Krishna1, W.R. Brugge2, J.M. Dewitt3, P. Kongkam4, B. Napoleon5, C. Robles-Medranda6, D. Tan7, S. El-Dika1, P. Hart1, D. Conwell1; 1Ohio State University Medical Center, Columbus, OH/United States of America, 2Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, 3Indiana University/United States of America, 4Chulalongkorn University/Thailand, 5Hôpital Privé Jean Mermoz/France, 6Ecuadorian Institute of Digestive Disease/Ecuador, 7Singapore General Hospital/Singapore

P1-82
TWO GASEOUS TRANSMITTERS IN L-ORNITHINE-INDUCED ACUTE PANCREATITIS IN RATS. S. Chooklin, S. Chuklin, B. Fidhirnyy; Regional Clinical Hospital, Lviv/Ukraine

P1-83
NECROTIZING PANCREATITIS FOLLOWING PARTIAL PANCREATICODUODENECTOMY: AN ANALYSIS OF 1253 CONSECUTIVE CASES. M. Loos, M. Dietrich, O. Strobel, U. Hinz, M.W. Büchler, T. Hackert; Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany

P1-84
ELEVATED PLASMA SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (P-SUPAR) ON RECOVERY AFTER FIRST ACUTE ALCOHOL-INDUCED PANCREATITIS (AAP) PREDICTS 10-YEAR MORTALITY. A. Aronen1, J. Aittoniemi2, R. Huttunen3, A. Nikkola1, J. Nikkola1, O. Limnell4, I. Nordback1, J. Sand1, J. Laukkanen1; 1Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere/Finland, 2Finlab Laboratories, Tampere/Finland, 3Department of Internal Medicine, Tampere University Hospital, Tampere/Finland, 4School of Medicine, University of Tampere, Tampere/Finland

P1-85
THE RATE OF POST-ERCP PANCREATITIS ASSOCIATED WITH SINGLE OPERATOR PERORAL SPYGLASS CHOLANGIOSCOPY (SOC) IS WELL TOLERATED WITH AN ESTABLISHED PRACTICE. A. Siiki1, M. Ukkonen1, J. Laukkanen1; 1Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland, 2Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland

P1-86
INCREASED SEMAPHORIN 3C PROMOTES TUMOR GROWTH AND METASTASIS IN Pancreatic Ductal Adenocarcinoma BY INACTIVATING PI3K/AKT SIGNALING PATHWAY. X. Xu, H. Wang; Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing/China

P1-87
8Seattle Children's Hospital/United States of America, 9Hospital for Sick Children/Canada, 10UCSF/United States of America, 11Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center/United States of America, 12Children's Hospital Los Angeles/United States of America, 13Montreal Children's Hospital/Canada, 14Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, 15UNSW/Australia, 16University of Utah/United States of America, 17MCW/United States of America, 18Hadassah Hebrew University Hospital/Israel, 19University of Iowa/United States of America, 20Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America

P1-88
SENNOSIDE A AFFECT INTESTINAL MOTILITY BY REDUCING IL-1? AND TNF-? TO INCREASE CPI-17 IN SMALL INTESTINAL SMOOTH MUSCLE CELLS IN RATS WITH ACUTE NECROTISING PANCREATITIS. C. Zhang1, Z.Q. Lin1, W. Zhang2, X. Zhang1, C. Du1, P. Xue1, Q. Xia1; 1Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China/China, 2Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China/China

P1-89
THE MICRO-FORCEPS FOR PANCREATIC CYSTS: A GAME CHANGER? O. Yuksel1, O. Basar1, D. Yang2, J. Samarasena3, C.J. Dimai4, M.S. Waghi5, D.G. Forcione1, A.N. Ronald6, M.B. Pitman6, W.R. Brugge1; 1Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, 2Gastroenterology, University of Florida Health/United States of America, 3Gastroenterology, University of California/United States of America, 4Gastroenterology, Mount Sinai Hospital/United States of America, 5Gastroenterology, University of Colorado/United States of America, 6Pathology, Massachusetts General Hospital/United States of America

P1-90
EXTINCTION OF ABCB5 EXPRESSION IN PANCREATIC CANCER CELLS. T. Hank1, M.W. Herbst1, K. Hu1, D. Maennle1, A.S. Bauer2, K. Felix1, T. Hackert1, N. Giese1, O. Strobel1; 1Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg/Germany, 2Department of Functional Genomics, German Cancer Research Centre (DKFZ)/Germany

P1-91
DCLK1 REGULATES BMI-1 AND IS ASSOCIATED WITH CLINICAL OUTCOME OF PANCREATIC CANCER. O. Yongsheng, H. Wang; Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing/China

P1-92
PANCREAS DIVISUM IN PEDIATRIC ACUTE RECURRENT AND CHRONIC PANCREATITIS. T.K. Lin1, M. Abu-El-Haiaja1, J.J. Palermo1, J.D. Nathan1, M.E. Lowe2, B. Zimmerman3, I. Inspire3, A. Uc4; 1Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, 2Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America, 3University of Iowa/United States of America, 4Pediatrics, University of Iowa/United States of America

P1-93
EFFECT OF HEPARINS ON HISTONE CATABOLISM AND CELLULAR INJURY IN ACUTE PANCREATITIS. P. Szatmary1, T. Liu1, D. Criddle1, A. Tepikin1, R. Sutton2; 1Cellular and Molecular Physiology, University of Liverpool/United Kingdom, 2NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom

P1-94
MISDIAGNOSIS OF CHRONIC PANCREATITIS (CP) IN A U.K REGIONAL PANCREAS CENTRE. A.R.G. Sheel1, C. Halloran1, P. Ghanekh1, R.D. Baron1, M. Ratary1, J. Kleeff1, V. Yip1, J. Evans3, F. Campbell4, R. Sutton1, R. Ramesh5, J.P. Neoptolemos1, 2; 1Pancreatobiliary Surgery, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom, 2NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, 3Radiology, Royal Liverpool and Broadgreen University Hospitals Trust,
Liverpool/United Kingdom, 4Histopathology, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom, 5Gastroenterology and Endoscopy, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom

**P1-95**
EXPLORE THE PROTEIN PROFILE OF PANCREATIC CANCER-ASSOCIATED DIABETES. L. Oldfield1, C. Jenkinson1, T. Purenwal2, R. Sutton3, J.P. Neoptolemos4, W. Greenhalf1, E. Costello1; 1Department of Molecular and Clinical Cancer Medicine, The University of Liverpool, Liverpool/United Kingdom, 2Department of Diabetology and Endocrinology, Royal Liverpool University Hospital, Liverpool/United Kingdom, 3NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, 4NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom

**P1-96**
THE HEPARIN-BINDING PROTEOME IN MURINE EXPERIMENTAL ACUTE PANCREATITIS. Q.M. Nunes1, D. Su1, P.J. Brownridge2, C. Sun2, Y. Li2, W. Huang1, D.J. Rigden2, R.J. Beynon2, R. Sutton1, D.G. Fernig2; 1NIHR Liverpool Pancreas Biomedical Research Unit/United Kingdom, 2Department of Biochemistry, University of Liverpool/United Kingdom

**P1-97**
PREVALENCE AND OUTCOMES OF ACUTE PANCREATITIS (AP) IN OLDER ADULTS: RESULTS FROM A PROPENSITY MATCHED ANALYSIS OF NATIONWIDE INPATIENT SAMPLE (2008-2012). S. Munigala1, A. Duvvuri2, K.C. Kottapalli3, D. Subramaniam4, D. Subramaniam5, G. Trikudanathan6, D. Conwell7; 1Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, 2Internal Medicine, Kansas City Veterans Affairs Medical Center, KS/United States of America, 3Internal Medicine, Wheaton Franciscan Healthcare St. Francis Hospital, WI/United States of America, 4Internal Medicine, Saint Louis University Center for Outcomes Research/United States of America, 5Health Service Research, Internal Medicine, University of Kansas Medical Center, KS/United States of America, 6Medicine, GI, University of Minnesota, Minneapolis/United States of America, 7Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P1-98**
A NOVEL STRATEGY OF TARGETING INTERFERON GAMMA-INDUCED PROTEIN 10 TO INHIBIT INSTANT BLOOD MEDIATED INFLAMMATORY REACTION IN ISLET TRANSPLANTATION. G. Yoshimatsu1, M. Takita1, C. Darden1, C. Chang1, P.S. Saravanan1, M.C. Lawrence1, B. Naziruddin2; 1Islet Cell Laboratory, Baylor Research Institute, Dallas, TX/United States of America, 2Baylor University Medical Center, Dallas, TX/United States of America

**P1-99**
THE IMPACT OF DIABETES ON OUTCOMES IN ACUTE PANCREATITIS: A REPORT FROM THE NATIONWIDE INPATIENT SAMPLE. J. McNabb-Baltar1, A. Hinton2, D. Conwell3; 1Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, 3Ohio State University Medical Center, Columbus, OH/United States of America

**P1-100**
INHIBITION OF HISTONE ACETYLATION RESULTS IN PANCREATIC CANCER CELL DEATH AND APOPTOSIS. B. Giri1, S. Modi2, V. Sethi2, J. George2, B. Garg2, S. Banerjee2, A.K. Saluja3, V. Dudeja2; 1University of Miami, University of Miami, Miami/United States of America, 2University of Miami/United States of America, 3Surgery, University of Miami, FL/United States of America

**P1-101**
PIGMENT EPITHELIUM- DERIVED FACTOR (PEDF) INHIBITS NOTCH SIGNALING IN PANIN CELLS. J. Gong1, G. Belinsky2, C. Chung2; 1Yale University School of Medicine, CT/United States of America, 2VA CT Healthcare/ Yale University School of Medicine, CT/United States of America
P1-102
MEK RESISTANCE VIA AMPHIREGULIN MEDIATED EGFR-STAT3 ACTIVATION IN PANCREATIC CANCER. P. Lamichhane1, N.S. Nagathihalli1, J. Castellanos2, C. Shi2, C. Roberts1, M. Vansaun1, N. Merchant1; 1Surgery, University of Miami, Miami, FL/United States of America, 2Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, TN/United States of America

P1-103
INITIAL PAIN MANAGEMENT FOR CHILDREN PRESENTING TO A PEDIATRIC EMERGENCY DEPARTMENT WITH ACUTE PANCREATITIS. A.S. Grover1, V. Kadiyala2, S.F. Manzi3, 4, V.L. Fox1; 1Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA/United States of America, 2Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 3Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA/United States of America, 4Department of Pharmacy, Boston Children's Hospital, Boston, MA/United States of America

P1-104
BLOCKING DNA DAMAGE REPAIR IMPROVES EFFICACY OF THERAPEUTICS IN PANCREATIC CANCER. S. Srinivasan1, C. Shi2, C. Roberts3, M. Vansaun1, N. Merchant1, N.S. Nagathihalli1; 1Surgery, University of Miami, Miami, FL/United States of America, 2Vanderbilt University Medical Center, Nashville, TN/United States of America, 3Surgery, University of Miami/United States of America

P1-105
ACUTE PANCREATITIS (AP) EARLY READMISSION RATES IN UNITED STATES: RESULTS FROM A NATIONWIDE HOSPITAL READMISSIONS DATA. S. Munigala; Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America

P1-106
AC3/AC-ASSOCIATED PROTEIN 1 COMPLEX REGULATES ACTIN FILAMENT DYNAMICS IN PANCREATIC CANCER CELLS. H. Hassan, A. Newsom, S. Mehratra, M.E. Sabbatini; Biological Sciences, Augusta University, Augusta, GA/United States of America

P1-107
BLOCKING P2 RECEPTOR BY SURAMIN REDUCES THE SEVERITY OF ACUTE PANCREATITIS. A. Dixit1, J. George2, Y. Ryu1, H. Cheema1, V. Dudeja3, R. Dawra1, A.K. Saluja1; 1Surgery, University of Miami, FL/United States of America, 2Surgery, University of Miami/United States of America, 3University of Miami/United States of America

P1-108
HEME OXYGENASE-1 INHIBITION SENSITIZE PANCREATIC CANCER TO GEMCITABINE THERAPY. M.Y. Abdalla1, S. Rachagani2, N. Wasim2, S. Batra2, S. Kumar2; 1Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha/United States of America, 2Biochem and Molecular Biology, UNMC/United States of America

P1-109
OPTIMIZATION OF TARGETED RADIONUCLIDE THERAPY (TRT) FOR PANCREATIC CANCER. S.K. Gautam1, M.W. Nasser1, S. Gupta1, S.K. Batra1, 2, M. Jain1, 2; 1Biochemistry and molecular biology, University of nebraska medical center, Omaha, NE/United States of America, 2Fred and Pamela Buffett Cancer Center, Omaha, NE/United States of America

P1-110
ZOLEDRONIC ACID AS A NOVEL RADIOSENSITIZER FOR PANCREATIC CANCER. P. Seshacharyulu1, R.K. Nimmakayal1, S. Rachagani1, S. Kaur1, M.P. Ponnusamy1, 2, M. Jain1, 2, C. Lin1, 3, S.K. Batra1, 4; 1Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE/United States of America, 2Fred & Pamela Bullet Cancer Center, Epbley Institute for Research in Cancer and Allied Diseases, -, NE/United States of America, 3Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, -, NE/United States of America, 4Fred & Pamela Bullet Cancer Center, NE/United States of America
P1-111
COMPARISON OF CLINICAL COURSE AND OUTCOME OF ALCOHOL INDUCED AND GALLSTONE INDUCED ACUTE PANCREATITIS. R. Kochhar1, J. Samanta1, N. Dhaka1, V. Gupta2, T.D. Yadav3, S.K. Sinha1; 1Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, 2Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India

P1-112
GASTROINTESTINAL FISTULAE IN ACUTE PANCREATITIS. J. Samanta1, N. Dhaka1, S. Kochhar2, R. Prasad1, S.K. Sinha1, V. Gupta3, T.D. Yadav3, R. Kochhar1; 1Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, 2Radiodiagnosis, Govt Medical College and Hospital, Chandigarh/India, 3Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India

P1-113
CHARACTERISTICS AND LONG-TERM SURVIVAL OF RESECTED PANCREATIC CYSTIC NEOPLASMS (PCN) IN FINLAND 2000-2008. THE FIRST NATIONWIDE STUDY. Y. Vaalavuo1, A. Antila1, R. Ahola1, A. Siik4, M. Vornanen1, J. Sand1, J. Laukkarinen1; 1Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere/Finland, 2Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland

P1-114
PANCREATECTOMIES FOR METASTATIC TUMORS. Junli Wu1, Zipeng Lu1, Cuncai Dai1, Kuirong Jiang1, Wentao Gao1, Jianmin Chen1, Feng Guo1, Jishu Wei1, Chunhua Xi1, Yi Miao1; 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

P1-115
PANCREATECODUODENECTOMY WITH RESECTION AND RECONSTRUCTION OF REPLACED RIGHT HEPATIC ARTERY (RRHA). Kuirong Jiang1, Zipeng Lu1, Jishu Wei1, Jianmin Chen1, Feng Guo1, Junli Wu1, Wentao Gao1, Jie Yin1, Dong Xu1, Pengfei Wu1, Chunhua Xi1, Miao Yi1; 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

P1-116
MICROENVIRONMENTAL CUES ENRICH FOR GLYCOLYTIC CD133+ “STEM-LIKE” TUMOR INITIATING CELLS IN PanCREATIC CANCER. A. Chandra, P. Dauer, N. Sharma, A. Nomura, V. Gupta, A. Saluja and S. Banerjee Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America
P2-1
COMPARISON OF REMNANT INVAGINATION AND DUCT-TO-MUCOSA PANCREATICOJEJUNOSTOMY FOLLOWING WHIPPLES RESECTION: RANDOMIZED CLINICAL TRIAL IN PATIENTS AT HIGH RISK OF POSTOPERATIVE PANCREATIC FISTULA. S. Sanjeevi1, M. Del Chiaro1, B. Björnsson2, J. Sand3, R. Segersvård1, L. Lundell1, Å. Andrén-Sandberg1, C. Ansorge1; 1Div. of Surgery, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm/Sweden, 2Dept. of Surgery, Linköping University/Sweden, 3Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland

P2-2

P2-3
ENDOSOMAL REGULATORY PROTEIN D52 INTERACTS WITH ATG16L1 TO COORDINATE SECRETION AND AUTOPHAGY IN ACINAR CELLS. M. Cooley, D.D. Thomas, S. Messenger, G. Groblewski; University of Wisconsin/United States of America

P2-4
STATIN USE SHOWS INCREASED OVERALL SURVIVAL IN PATIENTS DIAGNOSED WITH PANCREATIC CANCER: A META-ANALYSIS. D. Wang1, E. Rodriguez1, E. Donath1, J. Barkin2, A. Pakravan1; 1Department of Medicine, University of Miami Miller School of Medicine, Atlantis, FL/United States of America, 2Department of Gastroenterology, University of Miami Miller School of Medicine, University of Miami Pancreas Center, Miami, FL/United States of America

P2-5
ACUTE PANCREATITIS ADMISSION TRENDS IN PEDIATRICS, A NATIONAL ESTIMATE THROUGH THE KIDS. M. Abu-El-Haija1, S. El-Dika2, A. Hinton2, D. Conwell2; 1Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P2-6
NOVEL ROLE OF PERITONEAL MESOTHELIAL CELLS THAT LEAD TO PANCREATIC CANCER PERITONEAL DISSEMINATION FORMATION. T. Abe1, K. Ohuchida1, S. Kibe1, Y. Ando1, H. Nakayama1, S. Takesue1, S. Endo1, K. Koikawa1, T. Okumura2, T. Moriyama1, K. Nakata1, Y. Miyasaka1, T. Manabe1, T. Ohhtsuka1, E. Nagai1, K. Mizumoto1, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University/Japan, 2Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan

P2-7
INTRACELLULAR TRYSINOGEN ACTIVATION IN PHAGOCYTING MACROPHAGES ACTS AS DAMP FUELING SEVERE ACUTE PANCREATITIS. M. Sendler1, F.-U. Weiss1, T. Wartmann2, W. Halangk3, M.M. Lerch1, J. Mayerle1; 1Department of Medicine A, University Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald/Germany, 2Division of Experimental Surgery, Otto-von-Guericke University Magdeburg, Germany/Germany, 3Division of Experimental Surgery, Otto-von-Guericke University Magdeburg, Germany/Germany

P2-8
THE ROUTINE CLINICAL YIELD OF MOLECULAR ANALYSIS FOR PRECISION MEDICINE IN PANCREATIC CANCER USING PANCREATIC FNA BIOPSY MATERIAL. J. Farrell1, J. Wong2, K. Burnett3, M. Baker3, T. Mane3; 1Yale University, CT/United States of America, 2University of Hawaii, HI/United States of America, 3Caris Life Science/United States of America
P2-9
KRAS MUTATION IMPARTS NEOPLASTIC POTENTIAL ON DUCT CELLS BUT NOT ACINAR CELLS IN A MOUSE MODEL OF OBSTRUCTIVE CHRONIC PANCREATITIS. F.C. Pan1, J. Kim2, C. Shi3, M.K. Washington3, J. Kopp4, M. Sander5, M. Gannon6, R.D. Beauchamp7, C.V. Wright1, A.L. Means8; 1Cell and Developmental Biology, Vanderbilt University Medical Center, TN/United States of America, 2Surgery, Vanderbilt University Medical Center/United States of America, 3Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, TN/United States of America, 4Pediatrics and Cellular and Molecular Medicine, University of California, San Diego/United States of America, 5Pediatrics and Cellular and Molecular Medicine, University of California, San Diego, CA/United States of America, 6Medicine, Vanderbilt University Medical Center, TN/United States of America, 7Surgical Sciences, Vanderbilt University Medical Center, TN/United States of America, 8Surgery, Vanderbilt University Medical Center, TN/United States of America.

P2-10
THE IMPACT OF INTEGRATED MOLECULAR PATHOLOGY ANALYSIS ON EUS GASTROENTEROLOGIST MANAGEMENT DECISIONS FOR PANCREATIC CYSTIC LESIONS. J. Nieto1, S. Jackson2, A. Lankarani1; 1Borland-Groover Clinic, Jacksonville, FL/USA, 2Clinical Development, Interpace Diagnostics Corporation, Pittsburgh, PA/USA.

P2-11
PREVALENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN HOSPITALIZED ACUTE PANCREATITIS (AP) PATIENTS – A POPULATION BASED COHORT STUDY. G. Trikudanathan1, C. Umaphathy2, S. Munigala3, D. Conwell4, S.G. Krishna4, 5; 1Medicine, GI, University of Minnesota, Minneapolis/USA, 2Internal Medicine, University of Pittsburgh, PA/USA, 3Saint Louis University Center for Outcomes Research (SLUCOR)/USA, 4Ohio State University Medical Center, Columbus, OH/USA, 5Ohio State University-Wexner Medical Center, Columbus, OH/USA.

P2-12
LOSS OF EZH2 DOES NOT ENHANCE ONCOGENIC KRAS-PROMOTED PDAC IN ADULT TISSUE UNLESS COMBINED WITH EVENTS THAT AFFECT ACINAR CELL MATURATION. K. Berger1, C. Johnson2, G. Lomberk3, C. Howlett4, R. Urrutia5, C. Pin6; 1Paediatrics, University of Western Ontario/Canada, 2Paediatrics, University of Western Ontario, London, ON/Canada, 3Medicine, Mayo Clinic College of Medicine, MN/USA, 4Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada, 5Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, MN/USA, 6Paediatrics, University of Western Ontario, London/Canada.

P2-13
THE PANCREAS-SPECIFIC ISOFORM OF SPCA2 AFFECTS STORE OPERATED CA2+ ENTRY. M. Fenech1, S. Brar1, P. Statopoulos2, C. Pin3; 1Physiology and Pharmacology, University of Western Ontario, London/Canada, 2Physiology and Pharmacology, University of Western Ontario, London, ON/Canada, 3Paediatrics, University of Western Ontario, London/Canada.

P2-14
RENALASE PROTECTS AGAINST PANCREATITIS BY ACTIVATING A PLASMA MEMBRANE CALCIUM ATPASE (PMCA). T. Kolodecki1, A. Reed1, K. Date1, 2, F.S. Gorelick3; 1Internal Medicine digestive diseases, Yale University/United States of America, 2Graduate School of Humanities and Science, Ochanomizu University/Japan, 3VA Connecticut Healthcare, CT/United States of America.

P2-15
ACCURATE ADMISSION TRANSCRIPTOMIC SIGNATURE OF THE SEVERITY OF ACUTE PANCREATITIS. B. Lane1, W. Huang1, Q.M. Nunes1, K. Altaf1, L. Rainbow2, J. Armstrong1, W. Greenhalf1, D. Fernig2, C. Hertz-Fowler2, A. Cossins2, F. Falciani3, S. Maskell4, 5, J. Armstrong2, W. Greenhalf1, D. Fernig2, C. Hertz-Fowler2, A. Cossins2, F. Falciani3, S. Maskell4, A. Morris5, R. Sutton1; 1NHRI Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospitals NHS Trust/United Kingdom, 2Functional and Comparative Genomics, Institute of Integrative Biology, University of Liverpool/United Kingdom, 3Department of Biochemistry, Institute of Integrative Biology, University of Liverpool/United Kingdom, 4Department of Electrical Engineering and Electronics, Faculty of Science and Engineering, University of Liverpool/United Kingdom, 5Department of Biostatistics, Institute of Translational Medicine, University of Liverpool/United Kingdom.
P2-16
ACTIVATION OF IL-1 SIGNALING IN CD133+ PANCREATIC CANCER CELLS. A. Nomura, V.K. Gupta, P. Dauer, V. Dudeja, A.K. Saluja, S. Banerjee; Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America

P2-17
OPPOSING EFFECTS OF TGF-β AND BMP2 ON MICRORNA-200B IN THE PANCREAS. P. Yu, K. Liu, Y. Cao, T. Ko; UTHealth/United States of America

P2-18
C-SRC IS INVOLVED IN PHYSIOLOGIC ZYMOMGEN SYNTHESIS AND PACKAGING THROUGH THE GOLGI IN PANCREATIC ACINAR CELLS. G. Singh, J.R. Yaron, K. Patel, R.N. Trivedi, C. De Oliveira, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

POSTERS

P2-19
CLINICAL ALLOGRAFT ISLETS POST-TRANSPLANT 3 YEAR FOR TYPE 1 DIABETES MELLITUS: 10 CASES REPORTED. Y. Yao, L. Wei, M. Yang, L. Luo, H. Xue, L. Luo, G. Xiang, H. Zou, G. Wang, C. Lai, S. Deng, X. Huang; Center of Cell Transplantation?Center of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of University of Electronic Science and technology?Sichuan Provincial People's Hospital, Chengdu/China

P2-20
SUSCEPTIBILITY GENES OF MURINE AUTOIMMUNE PANCREATITIS. S. Müller1, L. Borufka1, J. Bischof2, Y. Gupta2, F. Asghari1, 2, S. Möller2, H. Nizze3, S. Ibrahim2, R. Jaster1; 1Department of Medicine, Division of Gastroenterology, Rostock University Medical Center, Rostock/Germany, 2Institute of Experimental Dermatology, University of Luebeck/Germany, 3Institute of Pathology, Rostock University Medical Center/Germany

P2-21
MOLECULAR TRACING OF INVASIVE IPMN LESIONS AND RELATED ADENOCARCINOMA TO DEFINE DISTINCT ROUTES TO INVASIVE CARCINOMAS OF THE PANCREAS. Y. Ono1, Y. Omori2, M. Tanino3, K. Takahashi4, Y. Ambo5, T. Shinohara2, H. Nishihara3, S. Tanaka3, H. Maguchi4, H. Karasaki1, Y. Mizukami1; 1Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan, 2Department of Pathology, Teine Keijinkai Hospital/Japan, 3Department of Tumor Pathology, Hokkaido University School of Medicine/Japan, 4Center for Gastroenterology, Teine Keijinkai Hospital/Japan, 5Department of Surgery, Teine Keijinkai Hospital/Japan

P2-22
MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY IN ASSESSING PANCREATIC FUNCTION TESTING IN PEDIATRICS. A.T. Trout1, D.B. Wallihan2, M. Abu-El-Haija1; 1Cincinnati Children's Hospital Medical Center/United States of America, 2Charlotte Radiology, Charlotte/United States of America

P2-23
PREDICTING PANCREATITIS PHENOTYPE IN THREE SIBLINGS BASED ON A SHARED GENOTYPE. D. Vitale1, M. Abu-El-Haija2, T.K. Lin2; 1Cincinnati Children's Hospital Medical Center/United States of America, 2Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America

P2-24
GENOME-WIDE RNAI SCREENING IDENTIFIED METASTASIS SUPPRESSOR GENES IN AN ORTHOTOTOPIC PANCREATIC CANCER MOUSE MODEL. T. Xia, Y. Chen; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong/Hong Kong PRC
P2-25
LIQUID BIOPSY FOR EARLY DETECTION OF PANCREATIC CANCER. Y. Mizukami1, Y. Ono1, H. Karasaki1, M. Ogata1, A. Sugitani1, K. Koizumi2, S. Asahara3, K. Kawakubo4, T. Takahashi5, H. Maguchi5, K. Nagashima1; 1Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan, 2Center for Gastroenterology, Shonan Kamakura General Hospital/Japan, 3Department of Gastroenterology, Chiba Tokushukai Hospital/Japan, 4Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine/Japan, 5Center for Gastroenterology, Teine Keijinkai Hospital/Japan

P2-26
QUALITY OF LIFE PREDICTORS IN CHRONIC PANCREATITIS: A EUROPEAN COHORT STUDY. S.M. Robinson1, 2, S. Rasch3, S. Beer4, A. Mickevicius5, I. Valantienė6, R. Charnley1, 7Department of HPB Surgery, Newcastle upon Tyne Hospitals, Newcastle Upon Tyne/United Kingdom, 2Institute of Cellular Medicine Fibrosis Research Group, Newcastle University, Newcastle Upon Tyne/United Kingdom, 3II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München/Germany, 4Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig/Germany, 5Center of Hepatology, Gastroenterology and Dietetics, Vilnius University Hospital Santariskiu Klinikos/Lithuania, 6Lithuanian University of Health Sciences/Lithuania, 7Universitätsklinik und Poliklinik für Innere Medizin 1, Universitätsklinikum Halle (Saale)/Germany

P2-27
RISK FACTORS FOR PANCREATIC ATROPHY IN TYPE 1 AUTOIMMUNE PANCREATITIS: A NATIONWIDE SURVEY BY THE JAPAN PANCREAS SOCIETY. M. Kitano1, T. Ito1, S. Kawaz, K. Kubota3, T. Kamisawa4, K. Okazaki5, T. Shimosegawa6; 1Gastroenterology, Shinshu university school of medicine/Japan, 2Shinshu University/Japan, 3Gastroenterology, Yokohama City University Graduate School of Medicine/Japan, 4Tokyo Metropolitan Komagome Hospital/Japan, 5Ransai Medical University/Japan, 6Tohoku University Graduate School of Medicine/Japan

P2-28
CBL-C, AN EPITHELIAL-SPECIFIC DESTRUCTOR OF ACTIVATED RTKS, DETERMINES SUBTYPE, MOTILITY AND TUMORIGENICITY OF PANCREATIC CANCER CELLS. K. Hu1, M. Schenk1, A.S. Bauer2, T. Giese3, S. Keleg1, K. Felix1, S. Le Blanc1, D. Baumann4, S. Wendler1, T. Hackert1, R. Offringa4, N. Giese1, O. Strobel1; 1European Pancreas Centre, Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg/Germany, 2Department of Functional Genomics, German Cancer Research Centre (DKFZ)/Germany, 3Institute of Immunology, University Hospital Heidelberg/Germany, 4Department of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ)/Germany

P2-29
ANACARDIC ACID INHIBITS CELL GROWTH AND SYNERGIZES WITH CHEMOTHERAPEUTICS BY THE ACTIVATION OF CHMP1A. M. Park1, D. Upton2, V. Eversole2, M. Blackmon1, S. Craver1, D. Perkins2; 1KYCOM, University of Pikeville, Pikeville, KY/United States of America, 2Biology and Chemistry, University of Pikeville, Pikeville, KY/United States of America

P2-30
ALTERNATIVE DIAGNOSES FOR MILD ELEVATIONS IN PANCREATIC ENZYMES: A CASE SERIES DESCRIPTIVE STUDY. D. Lew, S.J. Pandol, E. Afghani; Cedars-Sinai Medical Center/United States of America

P2-31
WRAPPING OF PANCREATICOJEJUNOSTOMY WITH PGA MESH COULD PREVENT THE PANCREATIC FISTULA AFTER PANCREATODUODENECTOMY. J.S. Kang, Y. Han, J.-Y. Jang, H. Kim, J.R. Kim, W. Kwon, S.-W. Kim; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine/Korea, Republic of

P2-32
CLINICOPATHOLOGICAL ANALYSIS AND PROBABILITY PREDICTION OF INVASIVE CARCINOMA IN PATIENTS WITH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM. A. Wei1, D. He2, W. Hu1; 1Pancreatic Surgery Department, West China Hospital, Chengdu/China, 2Pathology Department, West China Hospital, Chengdu/China
P2-33
ENDOSCOPIC MINOR PAPILLA SPHINCTEROTOMY IS EFFECTIVE FOR THE TREATMENT OF SYMPTOMATIC SANTORINICELE: LONG-TERM RESULTS IN A LARGE SERIES. S.F. Crinò1, L. Bernardoni2, M.C. Conti Bellocchi2, G. Mallozzi3, R. Manfredi3, L. Frulloni1, A. Amodio1, A. Gabbrielli1; 1Gastroenterology, AOUI Verona Hospital Trust, Verona/Italy, 2Gastroenterology, AOUI Verona Hospital Trust/Italy, 3Surgery B, AOUI Verona Hospital Trust/Italy, 4Radiology, AOUI Verona Hospital Trust/Italy

P2-34
PREDICTIVE FACTORS FOR LONG-TERM SURVIVAL FOLLOWING HEPATECTOMY FOR LIVER METASTASES FROM PANCREATIC CANCER. A. Andreou, F. Klein, R.B. Schmuck, A.R. Noltsch, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany

P2-35
CORTICOTROPIN-RELEASING FACTOR RECEPTOR 2 (CRF2R) DEFICIENCY ALTERS METABOLIC AND PANCREATIC FUNCTION IN A SEX-SPECIFIC MANNER IN MICE. S. Paruthiyil1, E. Kaushal1, B. Hasdemir1, A. Bhargava2; 1Osher Center, UCSF, San Francisco/United States of America, 2ObGyn & Osher Center, UCSF, San Francisco/United States of America

P2-36
EARLY DRAIN FLUID LIPASE AS PREDICTOR OF POSTOPERATIVE PANCREATIC FISTULA AFTER PANCREATIC RESECTION: A PROSPECTIVE PILOT STUDY. T. Ingkakul, C. Pumpuang, A. Thienhiran, S. Hongjinda; Surgery, Phramongkutklao Hospital, Bangkok/Thailand

P2-37
DIFFERENTIATING BRANCH DUCT IPMN FROM MIXED DUCT IPMN: TEST CHARACTERISTICS OF PREOPERATIVE IMAGING MODALITIES. E.E. Ugbarugba, C. Grieco, B. Swanson, P. Hart, S. El-Dika, J. Walker, S. McCarthy, A. Manichuk, M. Dillhoff, C. Schmidt, D. Conwell, S.G. Krishna; Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P2-38
A HUNGARIAN FAMILY WITH HEREDITARY PANCREATITIS AND THE P.L104P MUTATION IN THE HUMAN CATIONIC TRYPsinogen. B.C. Nemeth1, A.V. Patai2, M. Sahin-Toth3, P. Hegyi4; 1First Department of Medicine, University of Szeged, Szeged/Hungary, 22nd Department of Internal Medicine, Semmelweis University, Budapest/Hungary, 3Department of Molecular and Cell Biology, Boston University Medical Campus, Boston, MA/United States of America, 4Department of Translational Medicine, University of Pecs, Pecs/Hungary

P2-39
TRANSGASTRIC THERAPEUTIC PANCREATIC HYPOTHERMIA AS A NOVEL THERAPY FOR ACUTE PANCREATITIS (AP). C. De Oliveira, K. Patel, V. Mishra, R.N. Trivedi, J. Bradley, J.R. Yaron, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

P2-40
CANNABIS INDUCED ACUTE PANCREATITIS: A SYSTEMATIC REVIEW. J.A. Barkin1, Z. Nemeth2, A.K. Saluja3, J.S. Barkin1; 1Dept of Medicine, Division of Gastroenterology, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, 2Dept of Health Informatics, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, 3Dept of Surgery, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America

P2-41
NODE-NEGATIVE DISEASE IN PANCREATIC CANCER MIGHT NOT PRESENT DIFFERENT TUMOR BIOLOGY. K.C. Honselmann, I. Pergolini, C. Fernandez-Del Castillo, A.L. Warshaw, K.D. Lillemoe, C.R. Ferrone; Department of Surgery, Massachusetts General Hospital, Boston/United States of America
P2-42
COMBINATION OF L1156F AND M470V IN CFTR GENE ASSOCIATED WITH ALCOHOLIC CHRONIC PANCREATITIS IN JAPANESE. S. Kondo1, K. Fujiiki2, S.B.H. Ko3, A. Yamamoto1, M. Nakakuki1, Y. Ito1, M. Kitagawa2, S. Narezue, H. Ishiguro1; 1Nagoya University Graduate School of Medicine/Japan, 2Department of Nutrition, Nagoya University of Arts and Sciences, Nisshin, Aichi/Japan, 3Keio University School of Medicine/Japan, 4Miyoshi Municipal Hospital/Japan

P2-43
GNAS AND KRAS: FREQUENT MUTATIONS IN IPMN. A.-K. Stadler1, S. Fritz2, M. Volkmar3, J.H. Youn4, A. Tampakis1, M. Gaida5, R. Offringa6, J. Werner7, T. Hackert1, M.W. Büchler1, O. Strobel1; 1Department of General Surgery, University Hospital Heidelberg/Germany, 2University of Heidelberg/Germany, 3DFKZ/Germany, 4University hospital Heidelberg/Germany, 5Institute of Pathology, Heidelberg University Hospital/Germany, 6Department of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DFKZ)/Germany, 7University of Munich/Germany

P2-44
ZINC MEDIATES PANCREATITIS RESPONSES IN IN VITRO AND IN VIVO MOUSE MODELS OF ACUTE PANCREATITIS. M.Y. Phadke1, F. Gorelick2, 3; 1Pediatric Gastroenterology, Yale University School of Medicine, New Haven, CT/United States of America, 2Digestive Diseases, Yale University/United States of America, 3Veterans Administration CT Healthcare/United States of America

P2-45
CCK RECEPTOR KNOCK-OUT PREVENTS PANCREATIC CANCER GROWTH FROM DIETARY FAT. S. Nadella1, J. Burks2, G. Inyang1, J. Wang1, R. Tucker1, J. Smith2; 1Medicine, Gastroenterology, Georgetown University, Washington, DC/United States of America, 2Medicine/ Gastroenterology, Georgetown University, Washington DC, DC/United States of America

P2-46
CHEMOTHERAPY-INDUCED SENESCENCE PHENOTYPE CONVERSE DRUG RESISTANCE IN PANCREATIC CANCER. Y. Zhang1, Y. Wang2, B. Ji1; 1CANCER BIOLOGY, MAYO CLINIC/United States of America, 2Biochemistry and Molecular Biology, MAYO CLINIC/United States of America

P2-47
NUTRITIONAL ASSESSMENT OF DIETARY INTAKE IN CHRONIC PANCREATITIS USING A WEB-BASED FOOD FREQUENCY QUESTIONNAIRE. P. Hart, P. Madril, K. Roberts, D. Conwell, K. Crockett, M. Ramsey, M. Nahikian-Nelms; Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH/United States of America

P2-48
PRO-FIBROGENIC GREMLIN IS A NOVEL MARKER OF PANCREATIC STELLATE CELLS. K. Liu1, Y. Cao1, C. Rastelliniì², J. Bailey1, C. Chao2, T. Ko1; 1UTHealth/United States of America, 2UTMB Health/United States of America

P2-49
SUCCESSFUL ABLATION OF LYMPH NODES USING IRREVERSIBLE ELECTROPORATION (IRE) IN A PORCINE SURVIVAL MODEL. S. Fritz1, 2, C.M. Sommer3, T. Longerich4, C. Kuhn-Neureuther5, B. Radeleff2, J. Werner6, J. Königer3, M.W. Büchler2, T. Hackert2; 1General, Visceral and Transplantation Surgery, Katharinenhospital, Stuttgart/Germany, 2University of Heidelberg/Germany, 3Katharinenhospital Stuttgart/Germany, 4University Hospital RWTH Aachen/Germany, 5AngioDynamics Heidelberg/Germany, 6University of Munich/Germany

P2-50
AUTOPHAGY DRIVES PANCREATIC STELLATE CELLS ACTIVATION AND PROMOTES Pancreatic Cancer. S. Endo1, K. Nakata1, K. Ohuchida1, Y. Ando1, S. Kibe1, S. Takesue1, H. Nakayama1, T. Abe1, K. Koikawa1, T. Okumura1, Y. Mizuochi1, T. Moriyama1, Y. Miyasaka1, T. Manabe1, T. Ohtsuka1, E. Naga1, K. Mizumoto1, Y. Oda1, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University/Japan, 2Department of Anatomical Pathology, Kyushu University/Japan

47TH ANNUAL MEETING OCTOBER 26-29, 2016 BOSTON, MA 48
P2-51 RNA SEQUENCING REVEALS THERAPEUTIC EFFECTS OF MULTIPLE STATINS ON PANCREATIC CANCER CELLS. J. Yu1, S.-H. Liu1, R. Sanchez1, W. Fisher2, F.C. Brunicardi1; 1Surgery, UCLA, Los Angeles/United States of America, 2Baylor College of Medicine, TX/United States of America

P2-52 EFFECT OF THE MEDICARE SEVERITY-DIAGNOSIS RELATED GROUP CLASSIFICATION SYSTEM ON PREDICTING HOSPITAL READMISSION AFTER DISTAL PANCREATECTOMY. D. Xourafas, C. Fernandez-Del Castillo, A.L. Warshaw, K.D. Lillemoe, C.R. Ferrone; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, MA/United States of America

P2-53 LOW SERUM PANCREATIC AMYLASE AND LIPASE LEVEL VALUES ARE SIMPLE AND USEFUL PREDICTORS TO DIAGNOSIS OF CHRONIC PANCREATITIS. H.-C. Oh1, C.-I. Kwon1, J. Easler1, I. El Hajj1, J. Watkins1, E. Fogel1, L. McHenry1, S. Sherman1, M. Zimmerman2, G. Lehman1; 1Gastroenterology and Hepatology, Indiana University, IN/United States of America, 2Pathology and Laboratory Medicine, Indiana University, IN/United States of America

P2-54 XBP1 GENETIC DELETION ACCELERATES TUMOR PROGRESSION IN KRAS-INDUCED PANCREATIC TUMORIGENESIS. H.-Y. Su, R.T. Waldron, J. Yang, C. Hu, H. Hurley, S.J. Pandol, A. Lugea; Cedars-Sinai Medical Center/United States of America

P2-55 FATTY ACID UPTAKE VIA CD36 ENHANCES INVASIVENESS OF PANCREATIC CANCER CELLS. T. Okumura1, K. Ohuchida2, T. Moriyama1, K. Nakata1, Y. Miyasaka1, T. Manabe1, T. Ohtsuka2, E. Nagai1, K. Mizumoto1, M. Nakamura1; 1Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, 2Department of Surgery and Oncology, Kyushu University/Japan


P2-57 BENEFICIAL EFFECTS OF BERBERINE ON ACUTE NECROTIZING PANCREATITIS AND ASSOCIATED LUNG INJURY. S.-J. Park, G.-S. Bae, D.-G. Kim, M.J. Kim, S. Choi, J.H. Jeong; Herbology, WonKwang University/Korea, Republic of

P2-58 PANCREATICOGASTROSTOMY. H. Bari, T. Chawla, S. Effendi; General Surgery, Aga Khan University Hospital/Pakistan

P2-59 PATIENT-REPORTED LONG-TERM OUTCOME AFTER DUODENUM-PRESERVING PANCREATIC HEAD RESECTION (BERNE MODIFICATION) FOR CHRONIC PANCREATITIS. W. Niesen, T. Hank, U. Hinz, C. Scheele, J. Kaiser, T. Hackert, M.W. Büchler, O. Strobel; Department of General Surgery, University Hospital Heidelberg/Germany

P2-60 SPHINCTER OF ODDI BOTULINUM TOxin INJECTION TO PREVENT PANCREATIC FISTULA AFTER DISTAL PANCREATECTOMY. U. Klaiber1, P. Sauer2, T. Kehayova1, P. Probst1, P. Knebel1, M.K.-M. Diener1, L. Schneider1, O. Strobel1, C.W. Michalski1, A. Ulrich1, M.W. Büchler1, T. Hackert1; 1Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany, 2Interdisciplinary Center of Endoscopy, University of Heidelberg, Heidelberg/Germany
P2-61
OUTCOMES OF SURGICAL MANAGEMENT FOR PANCREATIC NEUROENDOCRINE TUMORS (PNETS): A SINGLE-CENTER EXPERIENCE. X. Lu, B. Hou, Y. Zhou, D. Li; General Surgery, Guangdong General Hospital/China

P2-62
HSF1-AMPK NEGATIVE FEEDBACK LOOP PROMOTES INVASION AND METASTASIS OF Pancreatic Cancer. Z. Wang1, K. Chen2, Q. Xu3, Z. Wu1, Q. Ma1; 1Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University/China, 2First Affiliated Hospital of Xi'an Jiaotong University/China, 3Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University/China

P2-65
INDUCTION OF THE ARTERY FIRST APPROACH IN PANCREATICODUODENECTOMY FOR Pancreatic HEAD CANCER. H. Shimamura, H. Kodama, A. Endo, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai/Japan

P2-64
METACHRONOUS SECONDARY LESIONS AND RECURRENCE IN THE REMNANT PANCREAS AFTER PANCREATECTOMY FOR Pancreatic DUCTAL ADENOCARCINOMA. Y. Gotoh1, T. Ohtsuka1, S. Nakamura1, Y. Nakashima1, K. Date1, T. Fujimoto1, N. Mochidome2, Y. Mori1, Y. Sadakari1, K. Nakata1, Y. Miyasaka1, K. Ohuchida1, T. Manabe1, E. Nagai1, Y. Oda2, M. Nakamura1; 1Department of Surgery and Oncology, Kyoto University, Fukuoka/Japan, 2Department of Anatomic Pathology, Kyoto University, Fukuoka/Japan

P2-65
SPLEEN-PRESERVING DISTAL PANCREATECTOMY. T. Kawana, H. Shimamura, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai/Japan

P2-66
A CASE SERIES OF SECONDARY PANCREATIC CANCERS. Y. Alazzawi, M. Mahmoud, S. Han, W. Wassef; Gastroenterology, UMass Memorial Medical Center, Worcester, MA/United States of America

P2-67
IMPACT OF POSTOPERATIVE SHORT-TERM OUTCOMES ON THE SURVIVAL OF Pancreatic HEAD CANCER. T. Sugiura, Y. Okamura, T. Ito, Y. Ito, R. Ashida, K. Uesaka; Shizuoka Cancer Center/Japan

P2-68
NEW POTENTIAL ROLE FOR TRANSCRIPTION FACTOR EB IN DNA REPAIR. M. Groleau, B. Marchand, M.-J. Boucher; Medicine, University of Sherbrooke, QC/Canada

P2-69

P2-70
METFORMIN INHIBITS HYPOXIA INDUCED PSC ACTIVATION AND Pancreatic CANCER CELL VIABILITY AND INVASION. Q. Xu; Department of Hepatobiliary Surgery, Xi'an Jiaotong University, Xi'an/China

P2-71
THE MET RECEPTOR TYROSINE KINASE IS INDISPENSABLE FOR ACINAR REGENERATION FOLLOWING RECURRENT INJURY. I. Gaziova1, C. Elferink2, L. Elferink1; 1Neuroscience and Cell Biology, University of Texas Medical Branch, TX/United States of America, 2Pharmacology, University of Texas Medical Branch, TX/United States of America
P2-72
PARTICIPATION OF BILE ACID RECEPTOR FXR IN SUPPRESSION OF ACINAR CELL AUTOPHAGY IN HUMAN CHRONIC PANCREATITIS. X. Zhou1, L. Xie2, F. Bergmann3, V. Endris3, O. Strobel4, M.W. Büchler5, T. Hackert4, F. Fortunato2; 1Section surgical research, University Clinic Heidelberg, Heidelberg/Germany, 2Section of surgical research, University Clinic Heidelberg, Heidelberg/Germany, 3Institute of Pathology, University Clinic Heidelberg/Germany, 4Department of General Surgery, University Hospital Heidelberg/Germany, 5University Hospital Heidelberg/Germany

P2-73
ENCOURAGING OBSERVED 5-YEAR SURVIVAL WITH UPFRONT RESECTION AND ADJUVANT THERAPY FOR PANCREATIC DUCTAL ADENOCARCINOMA IN A LARGE CONTEMPORARY SERIES. O. Strobel1, P. Lorenz1, U. Hinz1, M. Gaida2, A.-K. Stadler1, F. Bergmann3, T. Hank1, H. Gros1, W. Niesen1, T. Hackert1, M.W. Büchler1; 1Department of General Surgery, University Hospital Heidelberg/Germany, 2Institute of Pathology, Heidelberg University Hospital/Germany, 3Institute of Pathology, University Clinic Heidelberg/Germany

P2-74
CHAI-QIN-CHENG-QI DECOCTION IMPROVES INTESTINAL MOTILITY BY REGULATING PROTEIN KINASE C- AND ADENYLATE CYCLASE-MEDIATED CA2+ RELEASE IN COLONIC SMOOTH MUSCLE CELLS IN RATS WITH ACUTE NECROTISING PANCREATITIS. Z.Q. Lin1, J. Guo1, W.W. Chen1, L.H. Deng1, X.Y. Zhang2, W. Huang1, J.A. Windsor3, R. Sutton2, P. Xue1, Q. Xia1; 1Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University, Chengdu/China, 2NIHR Pancreas Biomedical Research Unit, University of Liverpool/United Kingdom, 3Department of Surgery, University of Auckland/New Zealand

P2-75
REFINEMENT OF NODAL STAGING FOR PANCREATIC CANCER BASED ON THE NUMBER OF POSITIVE LYMPH NODES: A POPULATION-BASED PROPENSITY SCORE-ADJUSTED ANALYSIS. O. Strobel1, I. Tarantino2, R. Warschkow3, T. Hackert1, B. Schmied1, A. Ulrich1; 1Department of General Surgery, University Hospital Heidelberg/Germany, 2General Surgery, Heidelberg University Hospital/Germany, 3Department of Surgery, University of Western Ontario/Canada, 4Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, Children's Health Research Institute, London, ON/Canada

P2-76
THE LOSS OF ATRX PROMOTES SUSCEPTIBILITY TO KRAS-MEDIATED PANCREATIC DISEASE. C. Young1, C. Howlett2, C. Pin1; 1Physiology & Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, Children's Health Research Institute, London, ON/Canada, 2Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada

P2-77
TREATMENT RESPONSE OF PANCREATIC CANCER CELLS IS SIGNIFICANTLY IMPAIRED BY TUMOR ASSOCIATED STROMAL CELLS. R.B. Schmuck, C. Neumann, A. Schirmeier, F. Klein, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany

P2-78
THE LIVERPOOL IN SITU SUBTOTAL PANCREATECTOMY (LIVOCADO PROCEDURE) FOR THE TREATMENT OF SEVERE ADVANCED CHRONIC PANCREATITIS. J.P. Neoptolemos, A.R.G. Sheel, R.D. Baron, J. Kleeff; Pancreatobiliary Surgery, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom

P2-79
TARGETING THE NOTCH PATHWAY SHOWS NO EFFECT ON TUMOR STEM CELLS IN Pancreatic Adenocarcinoma. R.B. Schmuck, S. Elisabeth, F. Klein, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany
P2-80
L-CARNITINE SUPPLEMENTATION IMPROVED HEPATIC STEATOSIS AFTER PANCREATECTOMY. M. Nakamura1, K. Nakata1, K. Hino2, K. Yoshida2; 1Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, 2Department of Hepatology and Pancreatolog, Kawasaki Medical School, Kurashiki/Japan

P2-81
PROTECTIVE EFFECTS OF NECROSTATIN-1 IN EXPERIMENTAL ACUTE PANCREATEITIS. Y. Ouyang1, 2, L. Wen1, 2, D. Latawiec1, J. Armstrong1, M. Awais1, P.J. Gough3, J. Bertin3, R. Mukherjee1, R. Sutton1, D. Criddle2; 1NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, 2Cellular and Molecular Physiology, University of Liverpool/United Kingdom, 3GlaxoSmithKline, Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, PA/United States of America

P2-82
TARGETED POLYPLEX NANOPARTICLE TO GASTRIN INHIBITS GROWTH AND DECREASES METASTASES OF PANCREATIC CANCER. C. Mankongpaisarnrung1, J. Burks2, S. Nadella1, J. Wang1, J.-I. Hahn3, R. Tucker4, A. Mahmoud5, S. Stern5, J. Smith1; 1Medicine, Gastroenterology, Georgetown University, Washington, DC/United States of America, 2Medicine, Oncology, Georgetown University, Washington/United States of America, 3Chemistry, Georgetown University, Washington, DC/United States of America, 4Comparative Medicine, Georgetown University, Washington, DC/United States of America, 5NIH, Nanotechnology Characterization Lab, Frederick/United States of America

P2-83
EXPLORING MACHINE LEARNING METHODS TO DETERMINE PREDICTORS OF PANCREAS FUNCTION. V. Pidlaoam1, D. Conwell2; 1Gastroenterology, Hepatology and Nutrition, Ohio State University, OH/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P2-84
NOVEL METHODS FOR THE MEASUREMENT OF BLOOD FLOW IN EXPERIMENTAL ACUTE PANCREATEITIS. P. Szatmary1, A. Taylor1, T. Leather1, H. Poptani1, D. Criddle1, A. Tepikin1, R. Sutton2; 1Cellular and Molecular Physiology, University of Liverpool/United Kingdom, 2NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom

P2-85
ENHANCER OF ZESTE HOMOLOGUE 2 IS A KEY REGULATOR OF ACINAR TO DUCT CELL METAPLASIA. C. Johnson1, L. Yu2, L. Luyt3, R. Urrutia4, G. Lomberk5, C. Pin6; 1Paediatrics, University of Western Ontario, London, ON/Canada, 2Oncology, University of Western Ontario, ON/Canada, 3Chemistry, University of Western Ontario, ON/Canada, 4Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, MN/United States of America, 5Medicine, Mayo Clinic College of Medicine, MN/United States of America, 6Paediatrics, University of Western Ontario, London/Canada

P2-86
CAN HEMOSTASIS PRODUCTS PREVENT POSTOPERATIVE PANCREATITIC FISTULAS AFTER DISTAL PANCREATECTOMY. C.M. Kühlbrey, S. Kasper, U.T. Hopt, U.A. Wittel; General- and Viszeral Surgery, University Hospital Freiburg, Freiburg/Germany

P2-87
LASER CAPTURE MICRODISSECTION AND PROTEOMIC CHARACTERIZATION OF ACINAR CELLS FROM CAERULEIN TREATED MICE REVEALS SIGNIFICANT UP-REGULATION OF CYTOSKELETAL PROTEINS. J.P. Shapiro1, H. Komar2, B. Hancioglu3, L. Yu4, P. Hart1, Z. Cruz-Monserrate1, D. Conwell1, G. Lesinski1, 2; 1Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH/United States of America, 2Division of Medical Oncology, The Ohio State University Wexner Medical Center/United States of America, 3Biomedical Informatics, The Ohio State University/United States of America, 4Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University/United States of America
PORTAL VEIN THROMBOSIS (PVT) IN ACUTE PANCREATITIS (AP) IS ASSOCIATED WITH POOR CLINICAL OUTCOMES AND INCREASED RESOURCE UTILIZATION: A POPULATION BASED COHORT STUDY. G. Trikudanathan1, S. Munigala2, M. Arain3, K.C. Kottapalli4, R. Attam3, S. Amateau5, S. Mallery5, M.L. Freeman6; 1Medicine, GI, University of Minnesota, Minneapolis/United States of America, 2Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, 3Medicine, University of Minnesota, Minneapolis/United States of America, 4Internal Medicine, Wheaton Hospital, Milwaukee/United States of America, 5University of Minnesota/United States of America, 6Gastroenterology, University of Minnesota, Minneapolis/United States of America

PANCREATIC ENZYME REPLACEMENT THERAPY IN CHRONIC PANCREATITIS: SYSTEMATIC REVIEW AND META-ANALYSIS. W. Huang1, 2, D. Iglesia-Garcia1, 3, P. Szatmary1, I. Baston-Rey3, J. Gonzalez-Lopez4, G. Prada-Ramallal5, A. Sud1, R. Mukherjee1, Q.M. Nunes1, J.E. Domínguez-Muñoz3, R. Sutton1; 1NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, 2Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University/China, 3Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela/Spain, 4Department of Pharmacy, University Hospital of Santiago de Compostela/Spain, 5Department of Preventive Medicine and Public Health, University of Santiago de Compostela/Spain

ALTERED GUT MICROBIOTA IN PATIENTS WITH CHRONIC PANCREATITIS IS ASSOCIATED WITH ENDOCRINE DYSFUNCTION. S.M. Jandhyala, M. Arutla, D. Govardhan, D.N. Reddy, R. Talukdar; Medical Gastroenterology and Basic Sciences, Asian Institute of Gastroenterology, Hyderabad/India

REGIONAL DIFFERENCES IN TREATMENT STRATEGIES OF PANCREATIC CANCER: A FINNISH REGISTER STUDY COVERING THE ENTIRE NATION. R. Ahola1, H. Hölsä2, S. Kiskola2, P. Ojala2, A. Pirttili2, J. Sand1, J. Laukkariena1; 1Tampere University Hospital/Finnland, 2Tampere University/Finnland

INCREASED CAVEOLIN-1 AND CHOLESTEROL METABOLISM IN CD133+ TUMOR INITIATING CELLS REGULATE INVASION AND CHEMORESISTANCE IN PANCREATIC CANCER. V.K. Gupta1, A. Nomura2, P. Dauer3, N.S. Sharma4, V. Dudeja3, A.K. Saluja5, S. Banerjee6; Sylvester Cancer Center, University of Miami, Miami/United States of America, 2Surgery, University of Miami, FL/United States of America, 3University of Miami/United States of America, 4Department of Surgery, University of Miami, Miami/United States of America, 5Dept of Surgery, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, 6University of Miami, University of Miami, Miami/United States of America

TARGETING CANCER STEM CELLS WITH COMBINED INHIBITION OF MEK AND STAT3 IN PANCREATIC CANCER. C. Roberts1, M. Vansaun1, P. Lamichhane1, F. Messaggio1, K. Kovacs2, N. Nagathihalli1, N. Merchant1; 1Surgery, University of Miami, Miami, FL/United States of America

VALIDATION STUDY OF THE IAP/APA MANAGEMENT GUIDELINE IN ACUTE PANCREATITIS ON PROSPECTIVELY COLLECTED HUNGARIAN DATA. A. Parnciczky1, B. Kui2, A. Szentesi2, A. Bálazs3, A. Szucs2, D. Mosztkabacher5, J. Czimmer6, P. Sarlos6, J. Bajor6, S. Godi6, A. Vincze6, A. Illes6, I. Szabo6, G. Par6, T. Takacs2, L. Czako2, Z. Szepesi2, Z. Rakonczay2, F. Izbeki7, J. Gervain7, A. Halas7, S. Crai8, J. Novak8, I. Hritz9, C. Gog10, J. Sunegi11, M. Varga12, B. Bod13, J. Hamvas14, M. Varga-Muller15, Z. Papp15, M. Sahin-Toth16, P. Hegyi17, 1Heim Pal Children's Hospital, Budapest/Hungary, 2First Department of Medicine, University of Szeged/Hungary, 3First Department of Medicine, University of Szeged/Hungary, 4First Department of Surgery, Semmelweis University/Hungary, 5Department of Pediatrics, Balassa János Hospital of County Tolna, Szélszard/Hungary, 6First Department of Medicine, University of Pécs/Hungary, 7Szent György University Teaching Hospital of County Fejér, Székesfehérvár/Hungary, 8Pádvány Kálmán Hospital of County Békés, Gyula/Hungary, 9Bács-Kiskun County University Teaching Hospital, Kecskemét/Hungary, 10Healthcare Center
of County Csongrád, Makó/Hungary, 11 Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, Miskolc/Hungary, 12 Dr. Réthy Pál Hospital, Békéscsaba/Hungary, 13 Dr. Bugyi István Hospital, Szentes/Hungary, 14 Bajcsy-Zsilinszky Hospital, Budapest/Hungary, 15 Institute for Translational Medicine, University of Pécs/Hungary, 16 Department of Molecular and Cell Biology, Boston University Medical Campus, Boston, MA/United States of America, 17 Institute for Translational Medicine, University of Pecs, Pecs/Hungary

P2-95
MAIN PANCREATIC DUCT SIZE INDEPENDENTLY PREDICTS HISTOLOGICAL MAIN DUCT INVOLVEMENT, INTESTINAL PHENOTYPE, AND MALIGNANCY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM. V. Morales-Oyarvide1, I. Pergolini1, C.R. Ferrone1, M. Mino-Kenudson2, A.L. Warshaw1, K.D. Lillemoe1, C. Fernandez-Del Castillo1; 1 Department of Surgery, Massachusetts General Hospital, Boston/United States of America, 2 Department of Pathology, Massachusetts General Hospital, Boston/United States of America

P2-96
SHOULD PATIENTS WITH ESTABLISHED CHRONIC PANCREATITIS UNDERGO TESTING FOR CELIAC DISEASE? A.S. Nett, E.-J. Wamsteker, M. Dimagno; Medicine, University of Michigan/United States of America

P2-97
ASSESSING THE CLINICAL SIGNIFICANCE OF PRSS1 INTRONIC VARIANTS. E. Hegyi1, A.Z. Toth1, P. Hegyi2, M. Sahin-Toth1; 1 Department of Molecular and Cell Biology, Boston University, Boston/United States of America, 2 Department of Translational Medicine, University of Pecs, Pecs/Hungary

P2-98
RISK OF DIABETES MELLITUS IN PANCREATIC CANCER: RESULTS FROM A PROPENSITY MATCHED STUDY (2008-2012). S. Munigala1, D. Conwell2; 1 Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, 2 Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P2-99
RISK OF DIABETES MELLITUS IN CHRONIC PANCREATITIS: RESULTS FROM A PROPENSITY MATCHED STUDY (2008-2012). S. Munigala1, D. Conwell2; 1 Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, 2 Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

P2-100
IN CHRONIC PANCREATITIS, A PREDICTIVE MODEL FOR SMALL INTESTINAL BACTERIAL OVERGROWTH INFLUENCES DECISIONS TO TEST OR JUST TREAT. J. Baker1, M. Dimagno2, E. Wamsteker3, A. Lee3, R. Saad3; 1 University of Michigan, University of Michigan, Ann Arbor/United States of America, 2 GASTROENTEROLOGY, UNIVERSITY OF MICHIGAN, Ann Arbor, MI/United States of America, 3 University of Michigan, University of Michigan, Ann Arbor, MI/United States of America

P2-101
SODIUM SULFATE SUPPRESSES MULTIPLE DAMAGE-ASSOCIATED MOLECULAR PATTERNS IN VITRO. Z. Yuan1, X. Wang2; 1 Shanghai General Hospital, Shanghai/China, 2 Shanghai General Hospital/China

P2-102
MUTY-HOMOLOG MODULATES PANCREATIC CANCER CELL SURVIVAL AND CHEMORESISTANCE. G. Sharbeen1, J. Youkhanan1, A. Mawson1, J. McCarroll2, A. Akerman1, D. Goldstein1, P. Phillips1; 1 Pancreatic Cancer Translational Research Group, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW/Australia, 2 Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales/Australia
P2-103
MICRORNA-345 IN Pancreatic Cancer Pathogenesis. S. Rachagani1, M. Kalaga1, R. Pothuraju1, S.K. Batra1, 2, 3; 1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE/United States of America, 2Fred and Pamela Buffett Cancer Center/United States of America, 3Epplley Institute for Research in Cancer and Allied Diseases, NE/United States of America

P2-104
Comparison of Clinical Course and Outcome of Acute Pancreatitis, Recurrent Acute Pancreatitis and Acute on Chronic Pancreatitis. D.J. Sharma1, J. Samanta1, N. Dhaka1, V. Gupta2, A. Gulati3, S.K. Sinha1, R. Kochhar1; 1Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, 2Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India, 3Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh/India

P2-105
Da-Cheng-Qi Extract Identification and Therapeutic Potential in Experimental Acute Pancreatitis. T. Jin1, D. Du2, N. Shi1, R. Zhang3, Q.M. Nunes4, M. Chvanov5, D.N. Criddle5, W. Huang4, R. Sutton4, Q. Xia1; 1Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Center, West China Hospital, Sichuan University/China, 2West China-Washington Mitochondria and Metabolism Center, West China Hospital, Sichuan University/China, 3Laboratory of Ethnopharmacology, West China Hospital, Sichuan University/China, 4NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, 5Department of Cellular and Molecular Physiology, University of Liverpool/United Kingdom

P2-106
Characterizing Familial Chylomicronemia Syndrome: Baseline Data of the Approach Study. D.J. Blom1, A. Digenio2, V. Alexander3, E. Prokopczuk4, L. Hemphill5, O. Muñiz6, R.D. Santos7, J.L. Witztum5, S. Baum8; 1University of Cape Town/South Africa, 2Clinical Development, Akcea Therapeutics, Cambridge, MA/United States of America, 3Ionis Pharmaceuticals/United States of America, 4Akcea Therapeutics/United States of America, 5Massachusetts General Hospital/United States of America, 6Hospital Virgen del Rocio/Spain, 7University of Sao Paulo Medical Hospital/Brazil, 8Boca Raton Regional Hospital/United States of America

P2-107
PI3KsR3 Promotes the Progression of Pancreatic Cancer via NKX2-5/DUSP5/ERK1/2 Pathway. Yunpeng Peng1, Yi Zhu1, Zipeng Lu1, Lingdi Yin1, Jishu Wei1, Yi Miao1; 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

P2-108
Arterial Divestment Instead of Resection for Locally Advanced Pancreatic Cancer (LAPC). Yi Miao1, Cuncai Dai1, Kuirong Jiang1, Baobao Cai1, Lingdi Yin1, Zipeng Lu1, Junli Wu1, Wentao Gao1, Jianmin Chen1, Feng Guo1, Jishu Wei1; 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

P2-109
Comparison of Patency Rates and Clinical Impact Between Different Reconstruction Ways Following Portal/Superior Mesenteric Vein Resection During Pancreatectomy. Wentao Gao1, Xinglong Dai1, Cuncai Dai1, Kuirong Jiang1, Junli Wu1, Qiang Li1, Feng Guo1, Jianmin Chen1, Jishu Wei1, Zipeng Lu1, Min Tu1, Yi Miao1; 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China
KEITH D. LILLEMÖE, MD  
CHIEF OF SURGERY & SURGEON-IN-CHIEF,  
MASSACHUSETTS GENERAL HOSPITAL  
W. GERALD AUSTEN PROFESSOR OF SURGERY,  
HARVARD MEDICAL SCHOOL

INVITES YOU TO A

PRESIDENTIAL RECEPTION  
OCTOBER 26 2016 • 7PM  
GEORGIAN ABC, BOSTON PARK PLAZA

HONORING  
CARLOS FERNANDEZ-del CASTILLO, MD  
PRESIDENT, AMERICAN PANCREATIC ASSOCIATION  
JORGE & DARLENE PEREZ ENDOWED CHAIR IN SURGERY  
DIRECTOR, PANCREAS AND BILIARY SURGERY PROGRAM,  
MASSACHUSETTS GENERAL HOSPITAL  
PROFESSOR OF SURGERY, HARVARD MEDICAL SCHOOL

---

Sylvester Comprehensive Cancer Center is pleased to welcome

Ashok Saluja, Ph.D., as the Inaugural Director of the Sylvester Pancreatic Cancer Research Institute at the Miller School of Medicine. Dr. Saluja also serves as Sylvester’s Associate Director for Research Innovation, Senior Associate Dean for Research, and as Professor and Vice Chair of Surgery at the University of Miami Miller School of Medicine.

Sylvester also welcomes Sulagna Banerjee, Ph.D., Rajinder Dawra, Ph.D., Vikas Dudeja, M.D., and Mahendra Singh, Ph.D., to the Sylvester Pancreatic Cancer Research Institute. These investigators will complement the ongoing pancreatic cancer research of Nipun Merchant, M.D., and his team members, Michael VanSaun, Ph.D., and Nagaraj S. Nagathihalli, Ph.D.

We expect great things from these outstanding pancreatic cancer researchers and their teams.

Sylvester.org